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With the increase in antibiotic resistance and after several years of abandonment, the 
use of bacteriophages (phages), as antimicrobial agents, to destroy bacteria began to 
arouse interest in the scientific community. This has led to a huge phage research in 
different fields and currently several studies are ongoing with animals and humans. 
Pseudomonas aeruginosa is an opportunistic pathogen, which frequently colonizes 
wounds infections. It has been estimated that a high number of deaths caused by wound 
infections results of bacterial infection, often by antibiotic-resistant P. aeruginosa. 
The main target of this work was to explore the potential of phages in controlling 
multidrug-resistant (MDR) P. aeruginosa strains in vitro and ex vivo (human skin). 
A new bacteriophages (PA709) was isolated from sewage water samples collected from 
Hospital Universitário de Coimbra (HUC). A phage suspension (108 PFU mL-1) was 
obtained using the clinical strain P. aeruginosa 709 as host. After the characterization 
of the phage candidate, their capacity to lyse other MDR P. aeruginosa clinical isolates 
from Aveiro, Matosinhos and Coimbra was investigated. The ability of the phage to 
cause inactivation of P. aeruginosa 709 was evaluated in vitro and in ex vivo (human 
skin), at 37°C, using a multiplicity of infection (MOI) of 0.5 to 50. In the in vitro 
assays, the effect of a second dose application, added after 4 hours of incubation, was 
also tested. 
The lytic phage PA709 has an icosahedral head with a long contractile tail and a DNA 
molecule as nucleic acid, a morphology characteristic of members of the Myoviridae 
family. The phage PA709 show a relatively broad host range (infects 30% of the 51 
MDR P. aeruginosa clinical isolates), infecting different genotypes isolated in the three 
hospitals (Matosinhos, Aveiro and Coimbra). For the best MOI, the number of MDR P. 
aeruginosa 709 in the human skin in the presence of the phage decreased 4 logs after 2 
hours of incubation. The application of a second dose of phage did not increase the 
efficiency of the therapy. These results show that the phage PA709 was seen to have 
rapid lytic activity but the number of bacteria gradually increased after that. The 
occurrence of lysogeny and the development of resistance of the host to the phages 
could explain the bacterial re-growth. However, no evidence of lysogeny was observed 
after addition of mitomycin C and no resistant to PA709 phage was detected. 
In conclusion, phage PA709 presents some interesting features, namely high efficiency 
in the inactivation of MDR P. aeruginosa , a broad host range and high stability in 
stock suspensions and in ex vivo human skin. All these attributes make this phage very 
promising for the treatment of P. aeruginosa skin wound infections. However, more 
phages should be isolated in the future, for the formulation of cocktails which might 
improve the inactivation efficiency against P. aeruginosa human skin infections. 
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Com o aumento da resistência aos antibióticos e após vários anos de abandono, o uso 
de bacteriófagos (fagos), como agentes antimicrobianos, para destruir bactérias 
começou a despertar interesse na comunidade científica. Isto levou a uma enorme 
investigação dos fagos em diferentes áreas e actualmente muitos estudos estão em curso 
usando animais e humanos. Pseudomonas aeruginosa é um patogénico oportunista, que 
frequentemente coloniza infecções da pele. Foi estimado que o elevado número de 
mortes causado por infecções da pele resulta de infecções bacterianas, muitas vezes por 
P. aeruginosa com resistência aos antibióticos. 
O principal objectivo deste trabalho foi explorar o potencial do fago em controlar 
estirpes de P. aeruginosa multi-resistentes (MR) in vitro e ex vivo (pele humana). 
Um novo bacteriófago (PA709) foi isolado da água do esgoto do Hospital Universitário 
de Coimbra (HUC). A suspensão fágica (108 UFP mL-1) foi obtida usando a estirpe 
clínica P. aeruginosa 709 como hospedeiro. Após a caracterização do fago candidato, a 
sua capacidade em lisar outros isolados clínicos MR de P. aeruginosa de Aveiro, 
Matosinhos e Coimbra foi investigada. A capacidade do fago causar inactivação da P. 
aeruginosa 709 foi avaliada in vitro e in ex vivo (pele humana), a 37ºC, usando uma 
multiplicidade de infecção (MOI) de 0,5 a 50. Em ensaios in vitro, o efeito da aplicação 
de uma segunda dose, adicionada após 4 horas de incubação, foi também testada.  
O fago lítico PA709 tem uma cabeça icosaédrica com uma cauda longa e contráctil e 
molécula de DNA como ácido nucleico; morfologia característica dos membros da 
família Myoviridae. O fago PA709 infecta 30% dos 51 isolados clínicos MR de P. 
aeruginosa, indicando uma infecção relativamente ampla de hospedeiros. Para a melhor 
MOI, o número de P. aeruginosa 709 MR na pele humana, na presença de fago, 
diminuiu 4 logs após 2 horas de incubação. A aplicação de uma segunda dose do fago 
não aumentou a eficiência da terapia. Estes resultados confirmam que o fago PA709 
parece ter uma rápida actividade lítica, mas o número de bactérias aumentou 
gradualmente depois disso. A ocorrência de lisogenia e o desenvolvimento de 
resistência do hospedeiro ao fago pode explicar o re-crescimento bacteriano. No 
entanto, não foi observada a presença de lisogenia após a adição de mitomicina C nem 
a resistência ao fago PA709 foi detectada. 
Em conclusão, o fago PA709 apresenta algumas características interessantes, 
nomeadamente elevada eficiência em inactivar P. aeruginosa MR, uma infecção ampla 
de hospedeiros e elevada estabilidade na suspensão em stock e na pele humana. Todas 
estas características fazem este fago muito promissor para o tratamento de infecções na 
pele de P. aeruginosa. No entanto, no futuro mais fagos deverão ser isolados, para 
obter cocktails de fagos que podem melhorar eficientemente a inactivação contra 
infecções na pele humana de P. aeruginosa. 
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1. Introduction 
1.1. Bacteriophages 
 
1.1.1. Discovery of bacteriophages 
 
The story of the discovery of bacteriophages or phages has been controversial and 
subject to many debates. In 1896, in India, Ernest Hankin observed in waters of two rivers 
the existence of high antibacterial activity against Vibrio cholera (Deresinski, 2009). He 
suggested that an unidentified substance was responsible for this phenomenon. Two years 
later, identical observation was made by Gameleya, while he worked with Bacillus subtilis 
(Sulakvelidze et al., 2001). These findings have not been explored and, only 20 years later, 
this topic has again been introduced (Sulakvelidze et al., 2001).  
At the beginning of the twentieth century, Frederick Twort and Felix d'Herelle, 
independently, described entities that could destroy cultures of bacteria. D'Herelle named 
them bacteriophages. The name was formed from “bacteria” and “phagein” (to eat or 
devour, in Greek) (Sulakvelidze et al., 2001). In 1917, d'Hérelle published these 
observations, describing the general procedures for isolation bacterial viruses. The 
bacteriologist isolated phages for some pathogenic bacteria that caused diseases like 
cholera (Skurnik and Strauch, 2006). Moreover, d'Hérelle developed the method of 
quantification of viruses and other theories, including the replication cycle of the phage 
(Bratbak and Heldal, 1993). 
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1.1.2. Properties and classification of bacteriophages 
 
Bacteriophages are viruses that infect bacterial cells. It has been estimated that phages 
are ten times more numerous in the environment than bacteria, making them the most 
abundant entities on Earth (Ackermann, 2007; Skurnik and Strauch, 2006). 
Phages have two essential components, proteins and nucleic acids. Bacteriophage 
taxonomy is based on their shape, size, proteins as well as on their nucleic acid. Most 
phages have dsDNA, however, some have ssDNA, dsRNA or ssRNA (Matsuzaki et al., 2005). 
In total there are 17 families of phages (Figure 1.1) (Ackermann, 2001; Ackermann, 2007; 
Hanlon, 2007). 
 
Figure 1.1: Schematic representation of the families described in the classification of bacteriophages (Ackermann, 
2007). 
Tailed phages are classified into three families and represent about 96% of the phages 
reported (Skurnik et al., 2007). These phages are composed of an icosahedral head and tail, 
and all of them have dsDNA (Table 1.1) (Ackermann, 2001; Ackermann, 2007). The 
Myoviridae family has got a contractile tail, the Siphoviridae family a long tail not 
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contractile and the Podoviridae family a very short tail. These three families comprise the 
order Caudovirales (Table 1.1) (Ackermann, 2001; Ackermann, 2007; Hanlon, 2007).  
The other families, which only constitute 4% of reported phages, are cubic (polyhedral), 
filamentous or pleomorphic. They contain ds or ssDNA or RNA as the genome (Table 1.1) 
(Ackermann, 2001; Ackermann, 2007; Dabrowska et al., 2005). 
 
Table 1.1: Main characteristics of bacteriophages and their classification (Ackermann, 2007). 
Order Family Shape Nucleid acid Morphology 
Caudovirales Myoviridae Tailed ds DNA, linear Tail contractile 
Siphoviridae Tail long, non contractile 
Podoviridae Tail short 
 Microviridae Cubic 
(polyhedral) 
ss DNA, circular Capsomers 
 Corticoridae ds DNA, circular superhelical Complex capsid, lipids 
 Tectiviridae ds DNA, linear Inner lipid vesicle, pseudotail 
 Leviviridae ss RNA, linear Poliovirus-like 
 Cystoviridae ds RNA, linear segmented Envelope, lipids 
 Inoviridae Filamentous ss DNA, circular Long filaments, short rods  
 Lipothrixviridae ds DNA, linear Envelope, lipids 
 Rudiviridae ds DNA, linear TMV-like 
 Plasmaviridae Pleomorphic ds DNA, circular superhelical Envelope, lipids, no capsid 
 Fuselloviridae ds DNA, circular superhelical Lemon-shaped 
 Salterprovirus ds DNA, linear superhelical Lemon-shaped 
 Guttaviridae ds DNA, circular superhelical Droplet-shaped 
 
1.1.3. Bacteriophage infection 
 
The phages are metabolically inert in their extra cellular form. They are only able to 
self-reproduce as long as the host bacteria is present and their replication depends 
exclusively on the host intracellular machinery to translate their own genetic code 
(Dabrowska et al., 2005; Lorch, 1999). 
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Viruses can interact with their hosts in two major and distinctive ways, the lytic and 
lysogenic cycles of infection and more sporadically through pseudolysogeny. However, only 
lytic phages are suitable candidates for phage therapy since they may destroy bacteria 
(Almeida et al., 2009; Hanlon, 2007; Weinbauer, 2004).  
In the lytic cycle, they multiply in the host cell and lyse the bacterial cell to release 
newly formed phage particles. Firstly, the phage binds to specific receptors of bacteria 
(Goodridge, 2010; Weinbauer, 2004). This phase is called adsorption. Phages can use 
different parts of lipopolysaccharide (LPS), flagella, fimbriae and many other surface 
proteins as receptors. Bacteriophages may also use enzymes to break down the bacterial 
surface (Skurnik and Strauch, 2006; Wróblewska, 2006). Then the phage genome is injected 
into the host bacterium and occurs early gene expression. Most of the proteins produced in 
this phase are involved in the shutting down of the host bacterium systems and phage 
genome replication. In some cases, the early proteins degrade the host DNA (Goodridge, 
2010; Weinbauer, 2004). After replication of the phage genome, occurs the expression of 
the phage late proteins that are involved in the formation of new phage particles and lysis 
of host bacteria (Duckworth and Gulig, 2002). The phage head and tail are assembled and 
the phage genome is packaged. The bacteria are destroyed through lysis, resulting in an 
average release of 50 to 200 daughter particles (Huff et al., 2005) (Figure 1.2).  
In lisogenic cycle, the phage genome is integrated into the host cell DNA. Prophage 
DNA will be replicated when the host cell genome replicates and so daughter cells will 
inherit the viral DNA (Figure 1.2). The prophage can stay in a dormant state for long periods 
of time and may become activated and turn on the lytic cycle. The lytic cycle is induced 
spontaneously by chemical or physical agents such as radiation, pollutantes, changes in 
temperature and nutrient concentrations (Almeida et al., 2009; Weinbauer, 2004). At the 
end the newly formed phage particles will lyse the host cell. Lysogeny might be a viral 
survival strategy to ensure periods of low host density during nutrient starvation 
(Weinbauer, 2004).  
There is another phenomenon known as pseudolysogeny. However, unlike true 
lysogeny, the phage genome does not integrate into the host. Pseudolysogeny is a 
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condition in which the starved bacterial cell coexists in an unstable relationship with 
infecting viruses (Figure 1.2). In such host cells, there is insufficient energy available for the 
phage to initiate genetic expression leading to either a true temperate response or to the 
lytic response (Ripp and Miller, 1997). As nutrients are supplied to the bacterium, the  
pseudolysogens resolve into either true lysogeny or active production of virions (lytic 
cycle). The direct result of pseudolysogenic relationships is an extension of the effective 
phage half-lives in natural environments (Almeida et al., 2009; Ripp and Miller, 1997). The 
pseudolysogenic state was found to depend on the concentration of nutrients available to 
the host. As cells became more starved, the frequency of pseudolysogens increased (Ripp 
and Miller, 1997; Weinbauer, 2004). 
 
 
 
Figure 1.2: General phage life cycle. Adapted from Weinbauer (2004). 
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1.2. Human skin flora and wound infection 
 
Human skin has intrinsic properties that are important to prevent infection and 
promoting healing in wounds (Church et al., 2006; Cunha, 1998). This organ provides 
sensation, thermoregulation, biochemical, metabolic, immune functions and physical 
protection and prevents infection caused by pathogenic microorganisms (Church et al., 
2006).  
The normal microflora of the skin includes fungi and bacteria. In 1938, Price reported 
that microorganisms found on the skin can be divided into resident flora, composed of 
commensals that rarely damage the host, or transient flora which do not grow on skin and 
reflects the host level of personal hygiene, lifestyle, personal activities and level of 
environmental contamination (Price, 1938). 
The predominant bacterial resident flora of the skin is various species of coagulase-
negative staphylococci (Staphylococcus epidermidis), Corynebacterium spp. and 
Propionibacterium spp. (Cunha, 1998). The Gram-negative bacteria often colonize healthy 
adult skin include Proteus sp., Enterobacter sp. and Klebsiella sp., Acinetobacter spp. and 
Pseudomonas spp., constituting about 25% of the adult skin microflora (Percival et al., 
2010). 
 
The bacteria become pathogenic soon they can adhere, grow and invade the host. 
Typically, soft tissue infections result from disruption of the skin by exogenous factor, 
extension from subjacent infection or disseminated through the blood stream from a 
distant site of infection. Most of skin and soft tissue infections are superficial, treated with 
local care and antimicrobial therapy (Cunha, 1998). Other factors predisposing to skin 
infections include vascular insufficiency, disrupted venous or lymphatic drainage, diabetes 
mellitus, previous cellulitis, foreign bodies, accidental or surgical trauma, burns, poor 
hygiene, obesity and immunodeficiencies (Cunha, 1998). 
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Pathogens causing initial infections are usually bacterial and the subsequent infections 
are caused usually by antibiotic-resistant bacteria. Antibiotics alter the balance of natural 
flora, leaving the surface vulnerable to colonization by exogenous gram-negative bacilli, 
yeasts and fungi which, usually occurs later due to the use of broad-spectrum antibiotic 
therapy (Church et al., 2006).  
Colonization with organisms, such as Gram-negative bacilli, is not favored. Enzymes and 
other metabolic products produced by Gram negative bacteria, enhance the invasive 
potential and the rapid spread of these infections (Church et al., 2006). Moreover, many 
Gram negative organisms are resistant to antibiotics, which mean it becomes difficult to 
eradicate (Tredget et al., 2004). Some bacteria are often organized in biofilms. These 
bioflms can form within 10 - 72 hours and acts as an effective barrier against host defenses 
and antimicrobial agents. (Kutter et al., 2010; Rode, 2010). In addition, the 
immunosuppressive state of the patient and the immediate lack of antibodies, allow 
multiplication of potential pathogens in the wound (Edwards-Jones and Greenwood, 2003).  
 
Infections by Pseudomonas aeruginosa 
P. aeruginosa is a non-fermentative, Gram negative bacilli and oxidase-positive. These 
bacteria is the main pathogen to cause wound infections, remain a major cause of sepsis, 
morbidity and high mortality (Church et al., 2006). Cause other diseases such as, 
pneumonia, bacteremia, meningitis, urinary tract infection, skin and soft tissue infections in 
immunocompromised individuals and hospitalized patients (Wróblewska, 2006). 
Colonization is more common in the respiratory tract, gastrointestinal tract and skin 
(Church et al., 2006). It is an opportunist pathogen that is notoriously unresponsive to 
many antibiotics. P. aeruginosa have many virulence factors, including structural 
components, toxins and enzymes (Table 1.2).  
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Table 1.2: Virulence factors of P. aeruginosa and its biological effects. 
Virulence factors Biological efects Reference 
Capsule 
growth as a biofilm; protection 
from innate and immune defenses 
(Drenkard and Ausubel, 2002; Govan 
and Deretic, 1996) 
Pili 
adherence to host (Govan and Deretic, 1996) 
Adhesins 
Lipid A 
Toxicity (Govan and Deretic, 1996) 
Lipopolysaccharide 
Exotoxins inhibition of protein synthesis 
(Edwards-Jones and Greenwood, 
2003; Govan and Deretic, 1996) 
Elastase 
tissue damage 
(Edwards-Jones and Greenwood, 
2003; Govan and Deretic, 1996) 
Protease 
Phospholipase C 
 
The capsule is composed by mucoid polysaccharides, which is important for growth as a 
biofilm in which bacterial cells are protected from innate and immune defenses, and 
become less susceptible to antimicrobials (Drenkard and Ausubel, 2002; Govan and 
Deretic, 1996). Its ability to form biofilm has been suggested to cause failure to heal in 
chronic wounds. The adherence to host is mediated by pili and adhesins (Govan and 
Deretic, 1996). The presence of lipid A and lipopolysaccharide (LPS) which is a component 
of the cell wall, enhances the toxicity of this microorganism (Govan and Deretic, 1996). 
Various toxins and enzymes are secreted, which causes inhibition of protein synthesis and 
cell death in the host. This causes local necrosis and can cause septicaemia (Edwards-Jones 
and Greenwood, 2003; Govan and Deretic, 1996). 
 
1.3 Bacterial resistance to antibiotics 
 
Chemotherapy has shown to be a rapid and effective method to treat or prevent 
microbial infections, but the regular use of antimicrobials has resulted in the development 
of drug resistance in common pathogenic microbial strains (Towner and Bergogne-Berezin, 
1996). Even though novel classes of antibiotics may be developed, the prospect that 
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bacteria will eventually develop resistance to the new drugs (Lorch, 1999), emphasize that 
effective antibiotics may not be available to treat seriously ill patients in the near future.  
Most antimicrobial agents used are categorized according to their principal mechanism 
of action. There are five major modes of action, disruption of bacterial membrane 
structure, interference with cell wall synthesis, inhibition of protein synthesis, interference 
with nucleic acid synthesis and inhibition of a metabolic pathway (Table 1.3) (Tenover, 
2006). 
 
Table 1.3: Mechanisms of action of antibacterial agents. Adapted from Tenover (2006). 
Mechanisms of action Antibacterial agents 
Disruption of bacterial membrane structure 
 
Increase bacterial membrane permeability  or 
membrane depolarization 
 
polymyxins, daptomycin 
 
Interference with cell wall synthesis 
 
Inhibit synthesis of the bacterial cell wall by 
interfering with the synthesis of the peptidoglycan 
layer 
β-Lactams: penicillins, cephalosporins, 
carbapenems, monobactams 
Glycopeptides: vancomycin, teicoplanin 
Protein synthesis inhibition 
 
Inhibit bacterial growth by binding to the 30S or 
50S subunit of the ribosome 
Macrolides, aminoglycosides, tetracyclines, 
chloramphenicol, streptogramins, and 
oxazolidinones 
Interference with nucleic acid synthesis 
 
Inhibit DNA or RNA synthesis 
 
Fuoroquinolones, rifampin 
Inhibition of metabolic pathway 
 
Inhibit DNA synthesis 
 
Sulfonamides, folic acid analogues 
 
Multidrug-resistant (MDR) strains can be defined as resistance to at least three classes 
of the antibiotics used in the treatment of these infections (Wróblewska, 2006). The 
hospital environment is the main focus for the emergence and spread of MDR bacteria. The 
emergence of MDR strains, usually occurs due to the selective pressure of antimicrobial 
therapy, i.e., inappropriate or excessive prescription of these chemicals, the frequent 
transmission of microorganisms and the truly large variety of mechanisms adopted by 
microbial cells to increase their resistance (Wróblewska, 2006). The direct relationship 
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between use of antimicrobial agents and prevalence of resistant bacteria has been 
documented on several occasions, particularly in Intensive Care Units (ICUs) (Aarestrup, 
1999).  
Bacteria can adopt mechanisms conferring resistance to antibacterial drugs. Some 
species of bacteria are innately resistant to one or more class of antimicrobial agents and 
others become resistant to an antibacterial agent (Wróblewska, 2006). The organism may 
acquire genes encoding enzymes, such as β-lactamases, that destroy the antibacterial 
agent before it can have an effect; may acquire efflux pumps that extrude the antibacterial 
agent from the cell before it can reach its target; may acquire several genes for a metabolic 
pathway which ultimately produces altered bacterial cell walls that no longer contain the 
binding site of the antimicrobial agent; or may acquire mutations that limit access of 
antimicrobial agents to the intracellular target site (Tenover, 2006; Wróblewska, 2006). 
P. aeruginosa are naturally resistant to a number of antimicrobials, such as ampicillin, 
amoxicillin, amoxicillin/clavulanate, cephalosporins of first and second generation, 
cefotaxime, ceftriaxone, nalidixic acid and trimethoprim. This intrinsic multidrug resistance 
occurs due to the synergy between broadly specific drug efflux pumps and the low degree 
of outer membrane permeability (Livermore, 2002; Pai et al., 2001; Wróblewska, 2006).  
Pathogenic bacteria that express multiple mechanisms of antimicrobial resistance, are 
associated to high financial costs and high mortality and morbidity in humans (Tenover, 
2006).  
The rising prevalence of antibiotic resistance in wound bacterial pathogens represents a 
serious therapeutic challenge for clinicians. At the same time, the pace of development of 
new antibiotics has been inadequate, resulting in a shortage of novel classes of 
antibacterial agents to eliminate MDR pathogens. This dramatic situation has created an 
urgent need for developing alternative for controlling such infections, especially wound 
infections who do not respond to conventional antibiotic therapies. One approach is phage 
therapy, where the bacteriophages can be applied locally on wounds. 
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1.4 Phage therapy 
 
Phage therapy is a non-antibiotic approach to inactivate microorganisms. It involves the 
application of bacteriophages, as antibacterial agents to combat bacterial infections 
(Duckworth and Gulig, 2002; Sulakvelidze et al., 2001). 
 
1.4.1 Discovery and history of phage therapy 
 
In 1919, the first time in France, d'Herelle applies the phage therapy in the treatment of 
cholera, obtaining therapeutic success (Lorch, 1999; Sulakvelidze et al., 2001). Phage 
therapy was vigorously investigated and numerous studies were undertaken to assess the 
potential of phage therapy for the treatment of bacterial infection in humans and animals 
(Lorch, 1999; Skurnik et al., 2007; Summers, 2001). Early success prompted the 
development of multiple commercial phage preparations. For example, in 1940 Eli Lilly 
Company produced seven phage products for human use (Housby and Mann, 2009). These 
preparations were used to treat infections that cause abscesses, purulent wounds, 
vaginitis, acute chronic upper-respiratory tract infections and mastoid infections (Fischetti 
et al., 2006; Housby and Mann, 2009; Sulakvelidze et al., 2001). 
However, with the development of antibiotics in the 1940s, interest in phage-based 
therapeutics declined in the Western world (Lorch, 1999; Sulakvelidze et al., 2001). Besides 
antibiotics, the most important factors that contributed to this decline was the lack of 
standardized testing protocols and methods of production and the beginning of World War 
II (Górski and Weber-Dabrowska, 2005; Lorch, 1999). Nevertheless, in Eastern Europe and 
the former Soviet Union, in centers such as the Eliava Institute of Bacteriophage, 
Microbiology and Virology in Tbilisi, Georgia and the Institute of Immunology and 
Experimental Therapy in Wroclaw, Poland, where access to antibiotics was limited, the 
development and use of phage therapy continued jointly with or in place of antibiotics 
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(Lorch, 1999; Summers, 2001). It is believed that the use of phages in these countries was 
due to two main reasons: phage therapy was used to treat the wounds of soldiers in World 
War II and the treatment was cheaper (Lorch, 1999). Much of the knowledge of the 
application of phage therapy is due to these research centers located in these eastern 
countries (Lorch, 1999; Summers, 2001).  
 
1.4.2 Pre - requisites for phage therapy 
 
The problems related to the production of phage complicated initial study and 
research. Diverse stabilizers and preservatives were initially used in attempts to increase 
the viability of the phage therapeutics (Summers, 2001). However, because the biology of 
both the phage and the various stabilizers were poorly understood, many of the 
ingredients added in an attempt to prolong the viability of phage preparations proved to be 
either toxic to humans (Summers, 2001).  
Another problem related to phage production was the purity grade of the preparations 
of these viruses. At the time, phage therapy preparations generally consisted of lysates of 
host bacteria that had been treated with the phage of interest (Skurnik et al., 2007). Thus, 
many preparations contained bacterial components (endo-and exotoxins) and products of 
lysis of the host that can cause some allergies or toxic effects when applied in humans 
(Skurnik et al., 2007). Accordingly, adverse events were often associated with the 
preparations, particularly in patients receiving them intravenously (Lorch, 1999).  
Today, microbiologists are aware of the need for advanced purification techniques to 
purify phages and to ensure that they are bacterium free. The viability and titer of phages 
should be determined before using them therapeutically (Skurnik et al., 2007; Sulakvelidze 
et al., 2001; Summers, 2001). The minimum requisites needed to use the phage in phage 
therapy, in order to minimize possible complications are summarized in the Table 1.4. 
 
-14- 
 
Table 1.4: Pre – requesites needed to use the phage in phage therapy. 
Pre - requisites for phage therapy 
Free of products of lysis techniques to purify phages 
Well characterization phage structure, behavior in vitro and in vivo 
Lytic lysogenic phages may carry genes that 
encode toxins or virulence factors 
Broad host range infecting members of the target species 
and/or genus 
Complete genome sequences know absence of any genes encoding 
pathogenicity associated or potentially 
allergenic proteins 
Sufficiently stable over storage and 
application 
determination of viability 
Amenable to scale up for commercial 
production 
efficacy against specific bacterial and no 
side-effects 
 
The phages used in phage therapy should be characterized in detail. It is necessary to 
sequence the genome of the phage, to identify its structure, test its behavior in vitro, and 
especially to prove their efficiency in vivo. Ideally, in the first place, should be tested in an 
animal model (Skurnik and Strauch, 2006).  
For phage therapy, lytic phages should be used and the development of lysogeny must 
be avoided. When lysogeny is established the host becomes immune to an infection caused 
by the same phage or phage related (Gill and Hyman, 2010). In addition, lysogenic phages 
may carry genes potentially dangerous from one host to another, such as genes that 
encode toxins or virulence factors, which may be toxic to humans (Alisky et al., 1998; 
Skurnik and Strauch, 2006; Sulakvelidze et al., 2001). For these reasons, we should 
sequence the whole genome of the phage, which will allow us to identify genes associated 
with presence of lysogenic cycle, such as the integrase and repressor gene (Skurnik et al., 
2007). 
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1.4.3 Advantages and disadvantages of phage therapy 
Advantages 
There are several potential advantages of phage therapy over chemotherapy (Table 
1.5).  
 
Table 1.5: Main advantages of the phage against the antibiotics 
Phages Antibiotics 
Very specific  Affects normal microflora 
Low resistance  High resistance 
Concentrated at the local of 
infection  
May not concentrated at the local 
of infection 
Low costs High costs 
No serious side effects Multiple side effects 
One single dose Multiple doses 
 
Phages are very specific to the target, while the antibiotics destroy pathogenic 
microorganisms and normal microflora. This affects the microbial balance in the patient, 
which may lead to serious secondary infections (Vinodkumar et al., 2008). The specificity of 
the host usually occurs at the level of strain, at the species level and rarely at the level of 
genus (Hagens and Loessner, 2010). The host range of phages is determined by receptors 
on the surface of the bacterium, allowing the binding of phage to bacteria (Skurnik and 
Strauch, 2006; Wróblewska, 2006). Therefore, first for an appropriate phage treatment, it 
will be necessary to identify the bacteria causing the infection and know which phages that 
infect bacterial strains. Secondly, it will be necessary to create databases with hundreds or 
thousands of phage preparations with different specificities (Balogh et al., 2010). 
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They have limited resistance development and selecting new phages is a relatively 
rapid process that can frequently be accomplished in days or weeks, while the antibiotics 
quickly become resistant to bacteria and the development of new antibiotics may take 
several years (Harcombe and Bull, 2005; Skurnik and Strauch, 2006; Sulakvelidze et al., 
2001).  
They are safe, no serious side effects have been described, because phages or their 
products (amino acids and nucleic acids) do not affect eukaryotic cells (Abedon and 
Thomas-Abedon, 2010; Gorski et al., 2003).  
The phages have the capacity to self-multiply at the site of infection, while the 
antibiotics do not necessarily concentrate at the site of infection (Skurnik et al., 2007). 
Systemic antibiotic therapy has little utility in patients with extensive wounds, because of 
poor penetration of the antibiotic into the wound, being the infection difficult to eliminate 
(Kutter et al., 2010). The reproductive ability of bacteriophage, avoids this problem. This 
makes phages ideal for wound treatment, in contrast to antibiotics, whose concentration 
decays rapidly with distance from the source and are eliminated by metabolic degradation 
or excretion (Brussow, 2005). Due to self-replication of the phage, the pharmacokinetics 
are problematic. The in vitro growth data for a phage cannot be directly applied to the in 
vivo situation and the in vivo data for one phage cannot be transferred to another phage. 
The use of phages as drugs may differ from antibiotics due to differences in the phage 
pharmacokinetics, which becoming the great challenge of phage therapy (Payne and 
Jansen, 2003). In simulations of the population and evolutionary dynamics of the phage–
bacteria interactions, the phage can eliminate all of the host bacteria in the culture. 
However, in reality, this cannot happen. There are, at least, three reasons for this not 
happen. First, the phages do not infect the host bacteria when their density is below the 
host cell threshold (Comeau et al., 2008). Second, the host may develop resistance to the 
phage (Levin and Bull, 2004). Third, the bacterial population might reach stationary phase 
and therefore might be physiologically refractory to the phage (Levin and Bull, 2004). 
However, in vivo the combination of phage and the host defenses are sufficient to keep the 
bacterial density below lethal threshold after phage therapy. Phage therapy only needs to 
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decrease the numbers of infecting bacteria to a level from which the host defenses can 
take care of the remaining bacteria (Levin and Bull, 2004). 
Finally, phage therapy is a technology flexible, fast, cheap and efficient against MDR 
pathogens, since the mechanism used by phage to lyse the bacteria is different from those 
used by antibiotics (Matsuzaki et al., 2005; Sulakvelidze et al., 2001). 
Disadvantages 
One of the disadvantages of phage therapy is the possible development of bacterial 
resistance to the phages. In phage infection, one essential step is the attachment of the 
phage onto specific receptors of bacteria. By mutating in the gene that encodes a bacterial 
product essential for losing the phage receptor, bacteria become resistant to phages (Levin 
and Bull, 2004; Skurnik and Strauch, 2006). However, this resistance cannot be serious. If 
the receptor used by the phage is a virulence determinant, loss of the receptor would 
decrease the virulence of the bacterium, and then it would be easier for the host immune 
system to eliminate the pathogen (Levin and Bull, 2004; Skurnik and Strauch, 2006). 
Furthermore, even if the bacteria becoming resistant to a particular phage is easier to find 
a new phage that can infect the pathogen than a new antibiotic (Harcombe and Bull, 2005; 
Skurnik and Strauch, 2006). In addition, the rate of mutation and replication is higher in the 
phage, which can overcome the adaptation of bacteria (Deresinski, 2009). Finally, 
according to some authors, the rate of development of bacterial resistance to phage is 10 
times less than the antibiotics (Carlton, 1999; Sulakvelidze et al., 2001). This rate may be 
much smaller if provided different phages in the same phage preparation. These cocktails 
of phages can be composed of two or more phages that use different receptors to infect 
bacteria of the same species or pathogenic bacteria more common for that particular 
infection (Goodridge, 2010). 
The lysogenic conversion can be another problem when phages are used to infected 
bacteria. When lysogeny is established the phenotype of the host cell can be altered. The 
temperate phage (prophages) can express some genes that can result in the production of 
toxins and antibiotic resistance (Alisky et al., 1998; Skurnik and Strauch, 2006; Sulakvelidze 
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et al., 2001). In addition, this host becomes resistant to infection by the same or similar 
strains of phages (Gill and Hyman, 2010). 
Another drawback is the possibility of phage particles were remove by the circulatory 
system of the host, i.e., phages can be neutralized by antibodies. However, first, the 
problem can be solved if it was prepared several phage strains with different antigens 
(James et al., 2004). Second, Duckworth and Gulig (2002) suggest that the kinetics of phage 
action is much faster than the production of antibodies by the host. Therefore, this 
neutralization is not significant during the initial treatment of infections. The phage therapy 
is complete before developing specific immunity (Duckworth and Gulig, 2002). 
 
 
1.4.4 Studies and applications developed in phage therapy 
 
1.4.4.1 Eastern Europe and the former Soviet Union 
 
In 1923 was founded the first institute of research on phage therapy, the Institute 
of Bacteriophage, Microbiology and Virology in Tblisi. Since 1950, the problem of antibiotic 
resistance was also known in the Union Soviet. Most resistant bacteria samples isolated in 
the Soviet Union were sent to Tblish in order to find phages corresponding to these 
bacteria (Lorch, 1999). Thousands of monophages and cocktail of phages (pyophage and 
intestiphage) for pathogenic bacteria strains, such as Staphylococcus, Streptococcus, 
Proteus, Pseudomonas aeruginosa and Clostrium were prepared (Kutateladze and Adamia, 
2008; Lorch, 1999). 
Scientist of the Eliava Institute continually renewed the cocktail pyophage and 
intestiphage with new phages against the most frequent and virulent strains for the 
prevention and treatment of wound infection and enteric bacteria, respectively 
(Kutateladze and Adamia, 2008). For deeper wounds, phages embedded in polymer called 
PhageBioderm is often used in addition to pyophage wound irrigation. PhageBioderm is a 
biodegradable, non-toxic polymer developed by Georgian chemists and microbiologists 
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since 1995 and approved for commercial release in 2000 (Kutateladze and Adamia, 2008; 
Kutter et al., 2010). As a result, very broad-range and effective bacteriophage preparation 
were obtained and the phage sensitivity of the infections was more than 85%. These 
preparations were used immediately for empiric phage therapy even before the bacterial 
sensitivity of the phage had been tested (Kutter et al., 2010). 
Research on bacteriophages was not limited to the Eliava Institute. For instance, 
one well-documented clinical phage therapy was carried out at the Institute for 
Immunology and Experimental Medicine, in Poland. While the western scientific 
community contributed to exchanging scientific results in English, the scientists of the 
Soviet Union were not included in the scientific community (Gorski et al., 2003; Lorch, 
1999). However, some of these studies and their applications are being translated and 
provided to English-speaking scientists. 
This institute, in Poland, has administrated phages against a variety of target 
microorganisms responsible for a number of diseases. They have a phage-bank, where they 
can choose one or more phages from their collections, which are active against a given 
bacterial isolate. Reportedly the Institute phage-bank presents over 300 specific 
bacteriophage strains against staphylococci, enterococci, Escherichia sp., Klebsiella sp., 
Salmonella sp., Shigella sp., Enterobacter sp., Proteus sp., Serratia sp., Acinetobacter sp. 
and Pseudomonas sp. (Kutter et al., 2010). 
In the past, phage were administered orally, topically or systemically to treat a wide 
variety of infections, such as suppurative wound, gastroenteritis, sepsis, osteomyelitis, 
dermatitis, emphysemas and pneumonia (Alisky et al., 1998; Sulakvelidze et al., 2001). 
 
Some of the clinical applications carried out in the Eastern Europe and former Soviet 
Union are summarized in Table 1.6.  
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Table 1.6: Clinical applications of phage therapy in Eastern Europe and the Soviet Union. Adapted from Sulakvelidze 
et al. (2001) 
Reference(s) Infection(s) Etiologic agent(s) Comments 
(Babalova et al., 
1968; Miliutina and 
Vorotyntseva, 
1993; Tolkacheva 
et al., 1981) 
Bacterial 
dysentery and 
salmonellosis 
Shigella, 
Salmonella, E. coli 
and Proteus 
The combination of phages and 
antibiotics was reported to be effective in 
treating cases where antibiotics alone 
were ineffective (Miliutina and 
Vorotyntseva, 1993).  
(Bogovazova et al., 
1992; Cislo et al., 
1987; Kochetkova 
et al., 1989; 
Sakandelidze, 
1991; Weber-
Dabrowska et al., 
2000; Zhukov-
Verezhnikov et al., 
1978) 
Infections of skin 
Pseudomonas , 
Staphylococcus., 
Klebsiella spp., 
Proteus, E. coli 
and Streptococcus 
31 patients having chronically infected 
skin ulcers were treated orally and locally 
with phages. The success rate was 74% 
(Cislo et al., 1987). 
65 patients received phages and the rest 
received antibiotics. Phage treatment was 
successful in 82% of the cases, and 
antibiotic treatment was successful in 
61% of the cases (Kochetkova et al., 
1989).  
(Ioseliani et al., 
1980; Meladze et 
al., 1982) 
Lung and pleural 
infections 
Staphylococcus, 
Streptococcus, E. 
coli and Proteus 
Phages were used to treat 223 patients 
and the results were compared to 117 
cases where antibiotics were used. Full 
recovery was observed in 82% of the 
patients in the phage-treated group, as 
opposed to 64% of the patients in the 
antibiotic-treated group (Meladze et al., 
1982). 
(Perepanova et al., 
1995) 
Inflammatory 
urologic diseases 
Staphylococcus, E. 
coli, and Proteus 
Adapted phages were used to treat acute 
and chronic urogenital inflammation in 46 
patients. The efficacy of phage treatment 
was 92% (marked clinical improvements) 
and 84% (bacteriological clearance) 
(Perepanova et al., 1995). 
(Sakandelidze, 
1991) 
Infectious 
allergoses 
(rhinitis, 
pharyngitis, 
dermatitis, and 
conjunctivitis) 
Staphylococcus, 
Streptococcus, E. 
coli, Proteus, 
enterococci, and 
P. aeruginosa 
360 patients were treated with phages, 
404 patients with antibiotics 576 patients 
with combination of phages and 
antibiotics improvement was observed in 
86, 48 and 83% of the cases, respectively 
(Sakandelidze, 1991). 
(Stroj et al., 1999) 
Cerebrospinal 
meningitis 
K. pneumonia 
Orally administered phages were used 
successfully to treat meningitis in a 
newborn (after antibiotic therapy failed) 
(Stroj et al., 1999). 
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1.4.4.2 West Europe 
 
Phage therapy research will gain momentum, while traditional antibiotic research has 
come to a stop in West Europe. Appropriately selected phages can easily be used to help 
prevent bacterial diseases in humans or animals, with potential for alternative applications 
and special interest for developing countries (Lorch, 1999). 
The use of bacteriophage therapy requires, however, a detailed understanding of the 
phage-bacteria interaction and of the awareness of various novel kinetics phenomena not 
known in conventional drug treatments and not considered in the Eastern Europe studies 
(Bull et al., 2002; Levin and Bull, 2004). Kinetics theory of phage therapy predicts that the 
average number of phage per bacterium, that is, the multiplicity of infection (MOI), the 
number of phage dose applications and the timing of the phage application are important 
in phage therapy and are now being studied in the west countries. 
 
In-vitro test 
One critical parameter that affects phage therapy is the initial phage dose that is the 
multiplicity of infection (MOI). High MOI is used when the experiment requires that every 
cell in the culture is infected, that is, the case of phage therapy. By contrast, low MOI is 
used when multiple cycles of infection are required. In vitro studies allows to study what 
the most appropriate MOI in order to obtain an effective inactivation of the host. It has 
been shown in vitro conditions that the reduction of pathogenic bacteria increased with 
the increase of the MOI (Table 1.7). Tanji et al. (Tanji et al., 2005) showed that, in vitro, 
Escherichia coli concentration did not change after phage addition at a MOI of 1. When 
applied at a MOI of 104, the bacterial density decreased 5 logs. Andreatti Filho et. al 
(Andreatti Filho et al., 2007) showed that the number of viable Salmonella enteritidis 
decreased 4 logs at a MOI of 100. However, at a MOI of 106 the bacterial density decreased 
7 logs. 
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All the literature reviewed, the number of phage doses applications and the timing of 
the phage application were not tested in vitro. 
Another critical parameter that should be tested in vitro is the host resistance 
developed to the phages. In most studies, the resistance of bacteria to the phage is not 
tested (Table 1.7). In several in vitro studies (Andreatti Filho et al., 2007; Kumari et al., 
2010; Tanji et al., 2005; Watanabe et al., 2007) it was observed a gradually increased in the 
bacterial number during the experiments of phage therapy. The authors speculate that 
these results may suggest the emergence of strains resistant to the phage. However, they 
do not actually test experimentally the development of bacterial resistance. Nevertheless, 
Loc Carrillo et al. (2005) concluded that Campylobacter jejuni develop resistance to two 
different phages after a phage therapy experiment. 
Table 1.7: In vitro study recently developed in West Europe 
Host Phage MOI Result Observation Reference 
Escherichia  
coli 
SP15, 
SP21, 
SP22 
1 No reduction --- 
Resistance: 
Speculate 
(no tested) 
(Tanji et al., 
2005) 104 
Reduction of 5 logs after 
8 hours of incubation 
A gradual increase 
in bacterial was 
observed 
Klebsiella 
pneumoniae 
Kpn5 0.1 
Reduction of 6 logs after 
3 hours of incubation 
A gradual increase 
in bacterial was 
observed 
Resistance: 
Speculate 
(no tested) 
(Kumari et 
al., 2010) 
Salmonella 
enteritidis 
WT45∅ 
100
 Reduction of 4 logs after 
6 hours of incubation A gradual increase 
in bacterial was 
observed 
Resistance: 
Speculate 
(no tested) 
(Andreatti 
Filho et al., 
2007) 106 
Reduction of 7 logs after 
6 hours of incubation 
Campylobacter 
jejuni 
CP34 300 
Reduction of 3 logs after 
8 hours of incubation 
A gradual increase 
in bacterial was 
observed 
Resistance: 
11% 
(Loc Carrillo 
et al., 2005) 
Pseudomonas 
aeruginosa 
KPP10 1 
Reduction of 4 logs after 
150 min of incubation 
A gradual increase 
in bacterial was 
observed 
Resistance: 
Speculate 
(no tested) 
(Watanabe 
et al., 2007) 
Pseudomonas 
aeruginosa 
MPK1 10 
Reduction of 5 logs after 
30 min of incubation A gradual increase 
in bacterial was 
observed 
Resistance: 
not 
referred 
(Heo et al., 
2009) 
MPK6 10 
Reduction of 4 logs after 
1.5 hours of incubation 
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Ex-vivo test 
To understand the phage-bacteria interaction in vitro tests are not sufficient, being 
necessary to resort to in ex vivo tests. The ex vivo tests do not fully mimic the in vivo 
growth conditions, but these tests allow experimentation under identical conditions than in 
vivo and under more controlled conditions. This methodology combines the advantages of 
in vivo with the flexibility of the in vitro.  
Up to my knowledge, there are a few ex vivo studies available in current literature 
(Atterbury et al., 2003; Goode et al., 2003). Goode et. al (Goode et al., 2003) showed that 
no Salmonella spp. or Campylobacter jejun were recovered, when they distributed on the 
surface of the chicken skin phage and their hosts at a MOI of 105. Atterbury et. al 
(Atterbury et al., 2003) demonstrated that Campylobacter jejuni decreased 1 log, after 
application of phage at a MOI of 10, on artificially contaminated chicken skin. 
All the literature reviewed, the number of phage doses applications, the timing of the 
phage application and the host resistance developed to the phages were not tested in ex 
vivo. 
 
In-vivo test  
As in vivo, the appropriate MOI must be tested to effectively reduce the number of 
viable pathogenic bacteria and increase the survival rate of the animal model. It has been 
shown in vivo conditions that the survival rates increased with the increase of the MOI 
(Table 1.8). Huff et. al (Huff et al., 2005) demonstrated that mortality was significantly 
reduced from 85 to 35% at a MOI of 1, and the birds were completely protected when the 
challenge culture was mixed with 108 PFU/ml of bacteriophage, MOI of 10,000. Wang et. al 
(Wang et al., 2006) studied the dose effect of phage in rescuing mice from lethal 
imipenem-resistant P. aeruginosa bacteremia and showed that higher doses of the phage, 
MOI of 0.01-200, 100% of the animals survived. As the phage dose decreased, MOI of 
0.0001 and 0.001, the animals became critically ill, showing survival rates of 0 and 20%, 
respectively. 
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The in vivo studies have been showed that the application of a single dose appears to be 
sufficient to control bacterial growth, contrarily to antibiotics (Table 1.8). Biswas et. al 
(Biswas et al., 2002) demonstrated that a single intraperitoneal injection of 108 PFU of the 
phage rescued 100% of Enterococcus faecium bacteremic mice. A similar study conducted 
by Smith and Huggins (Smith and Huggins, 1982) showed that all mice infected by E. coli 
survived with a single intramuscular dose of anti-K1 phage. 
Another critical parameter that can be well evaluated in vivo studies is the timing 
of the phage treatment. When the phage is administered too early, the phage will be 
released from the body before it reaches the replication threshold. When the phage is 
administered too late, the phage will not be effective (Table 1.8). Study by Smith and 
Huggins (Smith and Huggins, 1982) showed that when phages were administered in the 
same time that the mouse was infected with the E. coli, all mice survived. However, if the 
phage was administered two days after, 19 mice survived, and this number decreased to 1, 
when the phage was administered 7 days later. Another study done by this group showed 
that administration of phage 6 hours before or 18 hours after infection with E. coli, the 
mice developed diarrhea (Smith et al., 1987). This symptom did not happen if the phage 
was administered between 10 minutes before and 12 hours after infection with E. coli. 
The ability of phage to reach the infection site and access the host is another critical 
parameter that affects the phage therapy that can be studied in vivo using animal models 
(Table 1.8). Several studies show that for the same type of infection, the phage can be 
applied through different routes and some of them are more suited than others (Jikia et al., 
2005; McVay et al., 2007). McVay et. al (McVay et al., 2007) showed that the location 
where the phages were injected change the survival rate of mice. The mice was subjected 
to burn wound injury and to fatal infection with P. aeruginosa. Then, a phage cocktail was 
administered intramuscular (i.m.), subcutaneous (s.c.) or intraperitoneal (i.p.). The i.p. 
route providing the most significant protection (87%) of the routes tested. The phages 
administered by the i.p. route were delivered at a higher dose, earlier and for a more 
sustained period of time than the phages administered by the i.m. or s.c. route. Moreover, 
studies have already been made in implementing the phage locally to eliminate wound 
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infections instead of injecting, also showing good results. Study by Jikia et. al. (Jikia et al., 
2005) demonstrated that infections in human skin caused by Staphylococcus aureus were 
eliminated with the application of polymers embedded in a phage solution.  
Table 1.8: In vivo study recently developed in West Europe 
Host Animal 
model 
Phage/ administration MOI Results Reference 
Pseudomonas 
plecoglossicida 
fish Cocktail phage 
Orally 
1 Survival rates: 80% (Park and 
Nakai, 2003) 
Pseudomonas 
aeruginosa 
mice KPP10 
Orally 
100 Survival rates: 66.7% (Watanabe et 
al., 2007) 
Pseudomonas 
aeruginosa 
mice Cocktail phage 
 
intraperitoneal injection 
 
 
10
6
 
 
 
Survival rates: 87% 
(McVay et al., 
2007) 
intramuscular injection 10
6
 Survival rates: 28% 
subcutaneous injection 106 Survival rates: 22% 
Pseudomonas 
aeruginosa 
fly MPK6 
Orally 
1 Survival rates: 20% (Heo et al., 
2009) 
Pseudomonas 
aeruginosa 
mice ΦA392 
intraperitoneal injection 
0,01 Survival rates: 100% (Wang et al., 
2006) 0,0001 Survival rates: 0% 
Escherichia 
coli 
mice K12.K1 
intramuscular injection 
10 Survival rates: 94% (Smith and 
Huggins, 
1982) 
Escherichia 
coli 
chickens 
and calves 
R 
Orally 
intramuscular injection 
1 Survival rates: 100% (Lavigne et 
al., 2003) 
Escherichia 
coli 
chickens SPR02 
Aerosol 
1 Survival rates: 65% (Huff et al., 
2005) 10
4 
Survival rates: 100% 
Escherichia 
coli 
chickens  F78E  
Orally 
 
10 Survival rates: 25% (Oliveira et 
al., 2010) 
Escherichia 
coli 
mice Cocktail phage 
Orally 
1 Survival rates: 50% (Smith et al., 
1987) 
Enterococcus 
faecium 
mice ENB6 
intraperitoneal injection 
0.1 Survival rates: 100% (Biswas et al., 
2002) 
Staphylococcus 
aureus 
mice MSa 
intraperitoneal injection 
10 Survival rates: 97% (Capparelli et 
al., 2007) 
Klebsiella 
pneumonia 
mice KΦ1 
intraperitoneal injection 
100 Survival rates: 100% (Malik and 
Chhibber, 
2009) 
Klebsiella 
pneumonia 
mice SS 
intranasal inhalation 
100 Survival rates: 100% (Chhibber et 
al., 2008) 
Klebsiella 
pneumoniae 
mice Kpn5 
intraperitoneal injection 
10-
200 
Survival rates: 96.6% (Kumari et al., 
2010) 
0.1 Survival rates:53.33% 
0.01 Survival rates:13.33% 
0.001 Survival rates: 0% 
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Clinical trails 
Although the process of reintroduction of phage therapy in the West has been delayed, 
recently clinical cases in the West were conducted, which show the advances in clinical 
application of phage therapy (Table 1.9). 
A recent a study, done in Switzerland, with human volunteers receiving phage T4 
indicated that it is safe for oral administration (Bruttin and Brussow, 2005). No phage or 
phage T4-specific antibodies was detected in feces and in the serum of the human subjects. 
The number of E. coli in feces did not decrease and no adverse events related to phage 
application were reported. 
In the United Kingdom, Marza and colleagues  (Marza et al., 2006) reported the case of 
a 27 year old male with 50% surface area burns and skin grafts was applied. After several 
months, the patient became infected with P. aeruginosa and grafted areas broke down 
rapidly, despite appropriate antibiotic treatment. Therefore, treatment with phages was 
started. Three days after phage application, P. aeruginosa could no longer be isolated from 
swabs and subsequent extensive grafting was successful. 
Chronic otitis is a very common disease and very difficult to treat. Here, P. aeruginosa 
are often largely organized into biofilms and relatively protected from both antibiotics and 
immune cells, being particularly hard to eradicate. The Biocontrol scientists conducted a 
successful trial of phage against Pseudomonas dog ear infections (Wright et al., 2009). The 
results of that trial were necessary to obtain regulatory approval for a phase I/II in human 
trial. In humans infected with Psedudomonas sp., they applied a single dose of a phage 
cocktail with six different phages. The controlled clinical trial of a therapeutic 
bacteriophage preparation showed efficacy and safety. The company is now pursuing a 
phase III trial in the near future. 
Another phase I clinical study was performed to treat patients with venous leg ulcers 
(Rhoads et al., 2009). The cocktail phage, developed by Intralytix, contained eight 
individual phages (five were lytic for P. aeruginosa, two for S. aureus and one for E. coli). 
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Forty two patients with full thickness venous leg ulcers of over 30 days duration were 
included in the study. Patients received 50 ml of either diluted phage preparation or of 
sterile saline. Results of the study revealed no significant differences was determined 
between the test and control groups for frequency of adverse events, rate of healing, or 
frequency of healing. Efficacy of the preparation will need to be evaluated in a phase II. 
Some pre-clinical studies are already in study to inactive different bacteria, namely 
methicillin-resistant S. aureus strains (Table 1.9). 
Table 1.9: Clinical trials of phage therapy in West Europe 
Clinical infection/ 
bacterial agent 
Product Stage of 
development 
References 
Healthy human Orally phage Pre-clinical (Bruttin and Brussow, 
2005) 
P. aeruginosa 
Burns infections 
Discs soaked with 
phage solution 
Phase I/ II (Marza et al., 2006) 
P. aeruginosa 
Ears infections 
Cocktail of phage Phase I/ II (Wright et al., 2009) 
Venous leg ulcer 
infections 
Cocktail of phage Phase I (Rhoads et al., 2009) 
Mycoplasma mycoides Vaccines (orally 
phage) 
Phase I/ II (March et al., 2006) 
E. coli, Staphylococcus 
sp., Streptococcus sp., 
Pseudomonas sp. 
Phage for clinical 
trials 
Pre-clinical (BiophagePharma)(Can
ada) 
S. aureus Phage for clinical 
trials 
Pre-clinical (Gangagen) (India and 
USA) 
Methicillin-resistant S. 
aureus 
Phage for clinical 
trials 
Pre-clinical (Novolytics) (United 
Kingdom) 
Methicillin-resistant S. 
aureus, C . difficile, E. 
coli, K. pneumoniae 
and P. aeruginosa 
Phage products Pre-clinical and phase I (PhicoTherapeutics) 
(United Kingdom) 
Pseudomonas sp Phage for clinical 
trials 
Pre-clinical (PhageBiotech) (Israel) 
Methicillin-resistant S.  
aureus and P. 
aeruginosa 
Phage for clinical 
trials 
Pre-clinical (SpecialPhageHoldings) 
(Australia) 
S. aureus. 
Wound, systemic and 
respiratory infections 
Phage for clinical 
trials 
Pre-clinical (Viridax) (USA) 
 
In Portugal, there are two major companies also involved in the investigation of phage 
products, the Technophage SA in Lisbon and the Innophage in Oporto. 
 
-28- 
 
1.4.5 Phage therapy studies against Pseudomonas aeruginosa 
 
Different phages have been tested to inactivate a variety of P. aeruginosa strains (Table 
1.10) and in general, all these phage-bacteria interaction studies reveal that phages are 
capable of decreasing the number of viable bacteria, increasing the survival rate of the 
hosts (in vivo studies). Most of these studies did not evaluate the development of 
resistance by the bacteria (Table 1.10). The resistance development was only studied in 
two of the 28 studies considered in this revision and the results are very discrepant. 
Further studies are necessary to evaluate the importance of resistance development during 
phage therapy. 
 
Table 1.10: Use of bacteriophages to control Pseudomonas aeruginosa 
References Infections Tested Comments Resistance Phage(s) 
In vivo 
(Merabishvili et al., 
2009) 
burn wound Humans Stable, sterile and no 
cytotoxic 
- Cocktail-BFC1 
(Rhoads et al., 2009) venous leg ulcers Humans Efficacy and safety - - 
(Wright et al., 2009) chronic otitis Humans Efficacy and safety - Biophage-PA 
(Marza et al., 2006) burn wound Humans No recovered P. 
aeruginosa 
- - 
(Marza et al., 2006) chronic otitis Dog No recovered P. 
aeruginosa 
- - 
(Hawkins et al., 
2010) 
otitis Dog Redution: 56% - Cocktail 
(Heo et al., 2009) systemic 
infection 
Fly Survival: 20% - MPK6 
(Soothill, 1994) burn wound Guinea-pig Control P. 
aeruginosa 
- - 
(Velásquez, 2011) thermal injuries Mice Survival:100%-28% - Pa02 
(Heo et al., 2009) peritonitis sepsis Mice Survival:100%-40% - MPK6, MPK1 
(McVay et al., 2007) burn wound Mice Survival:87%-22% Resistance: 0% Cocktail 
(Vinodkumar et al., 
2008) 
septicemia Mice Survival:100% - CSV-31. 
(Wang et al., 2006) bacteremia Mice Survival:100% - ΦA392 
(Watanabe et al., 
2007) 
gut-derived 
Sepsis 
Mice Survival:67% - KPP10 
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(Soothill, 1992) septicemia Mice Survival:100% - BS24 
(Morello et al., 2011) cystic Fibrosis Mice Survival:100%-20% - PAK-P3 
(Debarbieux et al., 
2010) 
lung infections Mice Survival:100% - PAK-P 
(Hagens et al., 2004) septicemia Mice Survival:100% - Pf3R, Pt1 
In vitro 
(Ripp and Miller, 
1998) 
- - Reduction: 2 logs - UTI 
(Watanabe et al., 
2007) 
- - Reduction: 4 logs Speculated (no 
tested) 
KPP10 
(Hagens et al., 2004) - - Reduction: 4 logs - Pt1 
(Hagens et al., 2004) - - Reduction: 3 logs - Pf3R 
(Heo et al., 2009) - - Reduction: 5 logs - MPK1 
(Heo et al., 2009) - - Reduction: 4 logs - MPK6 
(Hanlon et al., 2001) - Biofilm Redution: 60% - F116 
(Fu et al., 2010) catheter Biofilm Redution: 99% Resistance: 90% M4 
(Ahiwale et al., 2011) catheter Biofilm Redution: 67% - BVPaP-3 
(Glonti et al., 2010) - Biofilm - - PT-6 
 
1.5 Final considerations 
 
The phages have several characteristics that make them attractive for use as 
therapeutic agents, however more studies will be done. Bacteriophages may be 
administered alone or in combination with antibiotics, and can be given prophylactically or 
as a therapy of infection. They offer many advantages, as they are very specific, replicate at 
the site of infection and no serious adverse effects of their administration have been 
described and they have low resistance. As a result of the emergence of MDR strains of 
pathogenic bacteria, we need a solution quickly. 
The aim of my work is to explore the potential of phages in controlling multidrug-
resistant P. aeruginosa strains in vitro and ex vivo (human skin). 
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2. Material and methods 
2.1 Bacterial strains, growth conditions and identification 
 
MDR Pseudomonas aeruginosa strains were isolated at the microbiology laboratory of 
the University Hospital of Coimbra (Hospital Universitário de Coimbra - HUC) (4 isolates), 
Local Health Unit of Matosinhos (Unidade Local de Saúde de Matosinhos - Pedro Hispano - 
ULSM) (27 isolates), Infante D. Pedro Hospital (Hospital Infante D. Pedro  Aveiro-HIDP) (17 
isolates) and Avelab Laboratory (3 isolates). The MDR Pseudomonas aeruginosa 709 
isolated by HUC was used as host to produce the phage stock suspension. The system 
BioMerieux Vitek 2® (BioMerieux) was employed to identify and characterize the profile of 
antibiotic susceptibility of the bacteria isolates. 
The 51 MDR isolates used in this study were cultivated in Tryptic Soy Broth (TSB; 
Merck) with agitation of 160 rpm at 37ºC for 4 hours. For each assay, an aliquot of this 
culture (240 µL) was subcultured in 30 mL of TSB medium and grew overnight at 37 °C 
under stirring (120 rpm) to reach an optical density (OD620) of ≈1.0, corresponding to ≈10
8 
cells mL-1. 
 
2.2 Genotyping of bacterial isolates  
 
For the molecular typing of the isolates a repetitive sequence PCR using a BOX A1R 
primer (5’-CTA CGG CAA GGC GAC GCT GAC G-3’) was followed (Rademaker et al., 2004). 
DNA was extracted using InstaGene Matrix kit (Bio Rad). BOX-PCR profiles were visualized 
after separation of PCR amplicons by electrophoresis in 1,5% agarose gel using 1x TAE (Tris-
Acetate-EDTA) at 100 V for 3 hours, stained with red gel. 
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2.3 Phage isolation 
 
Sewage water samples collected from HUC wastewater treatment plant were filtered 
by 0.45 µm-pore-size polycarbonate membranes (Millipore). The filtrate was added to a 
fresh bacterial culture in TSB. The mixture was incubated at 37ºC for 5 hours at 100 rpm 
and then centrifuged (10,000 x g, 10 minutes) (Thermo Haraeus Pico). The phage titer was 
determined by the double-layer method (Adams, 1959) using the centrifugated 
supernatant as phage suspension and Tryptic Soy Agar (TSA; Difco) as culture medium. The 
plates were incubated at 37ºC and examined for lysis plaques after 12 hours. Two more 
successive single-plaque isolations were performed to obtain pure phage stocks. The 
diameter of the lysis plaques was determined after incubation of the double-layer cultures. 
Phage stocks were stored at 4°C with 1% chloroform. 
 
2.4 Phage nucleic acid extraction and characterization 
 
Before nucleic acid extraction, phage particles were precipitated with polyethylene 
glycol (PEG) and separated by centrifugation (10,000 x g, 10 minutes). The pellets was 
resuspended in TE buffer [10 mM Tris HCl, 1mM ethylenediamine tetraacetic acid (EDTA), 
pH 8.0] (Sambrook and Russell, 2001). Extractions of nucleic acid from phage particles was 
performed using the protocol of Griffiths et al. (Griffiths et al., 2000). In order to amplify 
the phage nucleic acid kit was used the TempliPhi DNA Sequencing Template Amplification 
kit (Amersham Biosciences) was used as described by the manufacturer, with some 
adaptations. The template (2 µL) was added to 2 µL of distilled water and to 6 µL of sample 
buffer. A reaction premix was prepared (12 µL reaction buffer, 0.8 µL BSA (0.25 µg/µL) and 
0.5 µL enzyme mix) and after denaturation, 7 µL of this premix was added to each sample 
and incubated at 30°C for 4.5 hours. The reaction was terminated by heating at 65°C for 10 
min. 
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In order to characterize the phage nucleic acid, the nucleic acid extracts were subjected 
to digestion with DNase I (Ambion) and RNase I (Sigma Aldrich) as described by 
manufacturer. The reactions were terminated by heating at 80ºC for 5 min. Nucleic acid 
was visualized through agarose gel electrophoresis (1% agarose gel electrophoresis at 80 
V). 
 
2.5 Preparation of phages for transmission electron microscopy 
(TEM) 
 
The phage suspension was centrifuged directly onto formvar-coated carbon-stabilized 
400 mesh copper electron microscopy grids (Labometer) as described by Almeida et al. 
(Almeida et al., 2001). The viruses were ultracentrifuged at 100,000 x g for 1.30 hour at 
25ºC in a Beckman L8-80K ultracentrifuge equipped with a swing-out rotor (SW28). After 
centrifugation, the grids were negatively stained with 1.5% (w/v) uranyl acetate for 60 
seconds (Bratbak and Heldal, 1993), air-dried and examined with a Hitachi H9000 
transmission electron microscope at a magnification of 100,000× and an accelerating 
voltage of 200 kV. 
 
2.6 Phage host range analysis 
 
The 51 isolates of MDR P. aeruginosa were used for the determination of phage host 
range. Fresh bacterial cultures were separately added to molten soft TSA, overlaid on solid 
TSA and spotted with 10 μL of the phage suspension. Cultures were incubated at 37ºC for 6 
hours. Positive infection detected by the occurrence of lysis plaques. Each strain was tested 
in two independent assays. 
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2.7 Phage therapy in vitro 
 
In order to obtain 0.5, 10 and 50 MOI, 105 CFU mL-1 of P. aeruginosa 709 and a set of 
serial dilutions of phage suspension (104 to 106 PFU mL-1 ) were inoculated in TSB and 
incubated at 37ºC without agitation. For the MOI 10 assay, a second phage dose 
application (106 PFU mL-1) was also tested. The second dose was applied 4 hours after the 
first one. In the controls, the phage was not added to the bacterial cultures. Aliquots were 
collected at time 0 and 2, 4, 6, 8, 12 and 18 h of incubation for host and phage 
quantification. For quantification of the host, aliquots were serially diluted, and pour-
plated in duplicate, and incubated at 37ºC for 24 h. The phage title was determined in 
duplicate, by double-layered method, followed by incubation 37ºC for 18 h. Two 
independent experiments were conducted and the results were averaged. 
 
2.8 Phage therapy in ex-vivo human skin 
 
Samples of human skin, obtained from surgical procedures, were cut into sections of 10 
cm2, disinfected with povidone-iodine (PVPI) 10% and washed with saline solution. The skin 
sections were individually transferred to sterile petri dishes. An aliquot of 200 µL of an 
overnight culture of strain P. aeruginosa 709 was inoculated on the skin samples and the 
inoculum was evenly spread over the surface using a glass spreader. Gauze bandages 
soaked with phage solution (pH=7.3) were placed directly on the inoculated skin which was 
then incubated at 37°C in a humid atmosphere. Surface samples from the skin were 
collected from a defined area with cotton swabs at time 0 and 2, 4, 6, 8, 12 and 18 h of 
incubation and washed in PBS. The sample suspension was pour-plated, in duplicate on 
MacConkey agar (Merck) for quantification of the host bacteria and the results were 
expressed as CFU cm-2. For the quantification of the phage, the PBS suspension was serially 
diluted, plated by the double-layer method, incubated at 37°C during 18 h and the results 
expressed as PFU cm-2. The phage suspension was not added to the controls that were 
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otherwise treated as the tests. Experiments were conducted in duplicate and the results 
were averaged. 
 
2.9 Phage survival in vitro 
 
An aliquot of 1 mL of phage suspension (107 PFU mL-1) was inoculated in PBS and 
incubated at 37ºC without agitation. Sub-samples were collected at time 0 and 9, 15, 21, 
24, 27, 30 and 36 days incubations for phage quantification. The phage was quantified, in 
duplicate, by the double-layer method. Two independent assays were conducted and the 
the results were averaged. 
 
2.10 Phage survival in ex-vivo human skin 
 
Gauze bandages soaked in the phage solution (107 PFU mL-1) were place over samples 
of human skin and kept at 37°C in a humid atmosphere. Skin samples were collected at 
time 0 and 4, 5, 6 and 7 days of incubation for phage quantification. The phage was 
quantified, in duplicate, using the double- layer method. Two independent assays were 
conducted and the results were averaged. 
 
2.11 Detection of prophages in the host 
 
Mitomycin C (Sigma Chemical) was added to a P. aeruginosa 709 culture (1 μg mL-1) 
before and after 10 hours of incubation at 37°C with the phage PA709. The culture was 
incubated overnight at 37ºC and centrifugated (10,000 x g, 10 minutes) (Thermo Haraeus 
Pico). The spot test was performed using the supernatant as phage suspension. In the 
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control, mitomycin C was not added. Two independent assays were conducted and the 
results were averaged. 
 
2.12 Screening of host resistant strains 
 
After 8 and 10 hours of incubation at 37°C with the phage PA709, for MOI 10, an 
aliquot was plated in TSA in order to isolate bacteria colonies. Cultures were incubated at 
37ºC overnight. Five isolated colonies were purified by the streak-plating technique (3-5 
steps) and the purified isolates were cultured in TSA, in order to remove phage particles 
from the bacteria. To check if the strain remained sensitive to the phage, the isolated 
colonies were inoculated separately in TSB and tested by the spot procedure. Two 
independent assays were conducted for each isolate. 
 
2.13 Statistical analyses 
 
Statistical analysis was performed by using SPSS (SPSS 15.0 for Windows, SPSS Inc., 
USA). Normal distributions were assessed by the Kolmogorov-Smirnov test and 
homogeneity of variances was assessed by the Levene test. The significance of the 
difference in phage inactivation with different MOI and with different doses was evaluated 
by one-way ANOVA with the Bonferroni post hoc test. A value of P < 0.05 was considered 
as significant. 
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3 Results 
 
3.1 Bacterial strains 
 
MDR Pseudomonas aeruginosa strains isolated at the microbiology laboratory of the 
University Hospital of Coimbra (Hospital Universitário de Coimbra - HUC), Local Health Unit 
of Matosinhos (Unidade Local de Saúde de Matosinhos - Pedro Hispano - ULSM), Infante D. 
Pedro Hospital (Hospital Infante D. Pedro Aveiro -HIDP) and Avelab Laboratory (3 isolates) 
are presented in Table 3.1. 
 
Table 3.1: The 51 bacterial strains used in this study. ULSM, Unidade local de saude de Matosinhos; HUC, Hospitais da 
universidade de Coimbra; HIDP, Hospital Infante D. Pedro 
Bacteria Assigned by Bacteria Assigned by Bacteria Assigned by 
PA 709 HUC PA 261.1 ULSM PA 961 HIDP 
PA 826 HUC PA 088 ULSM PA 304 HIDP 
PA 519 HUC PA 800 ULSM PA 108 HIDP 
PA 548 HUC PA 845 ULSM PA 766 HIDP 
PA 17567 AVELAB PA 89 ULSM PA 1 HIDP 
PA 5531 AVELAB PA 876 ULSM PA 2 HIDP 
PA 372 AVELAB PA 512 ULSM PA 3 HIDP 
PA 025 ULSM PA 782 ULSM PA 4 HIDP 
PA 433 ULSM PA 1003 ULSM PA 5 HIDP 
PA 338 ULSM PA 722 ULSM PA 6 HIDP 
PA 531 ULSM PA 3169 ULSM PA 7 HIDP 
PA 154 ULSM PA 028 ULSM PA 8 HIDP 
PA 103 ULSM PA 916 ULSM PA 9 HIDP 
PA 701 ULSM PA 252 ULSM PA 10 HIDP 
PA 489 ULSM PA 777 ULSM PA 11 HIDP 
PA 61 ULSM PA 310 ULSM PA 12 HIDP 
PA 352 ULSM PA 926 ULSM PA 13 HIDP 
 
3.2 Resistance of bacterial strains to antibiotics 
 
Among the 51 bacteria studied, 70% of isolates showed resistance to ciprofloxacin, 
piperacillin/tazobactam, piperacillin and ticarcillin/clavulanic acid, 50% to 70% were 
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resistant to ceftazidime, imipenem, meropenem and ticarcillin. The most effective 
antibiotics against these strains are amikacin, tobramycin and colistin with a of 80%, 80% 
and 100%, respectively (Figure 3.1).  
 
 
Figure 3.1:  Relative frequency (%) of susceptibility, intermediate susceptibility and resistance to a range of common 
antibiotics among the 51 isolates. R: resistant; S: sensitive and I: intermediate; NA: amikacin; CAZ: ceftazidime; CIP: 
ciprofloxacin; GM: gentamicin; IPM: imipenem; MEM: meropenem; TZP: piperacillin/tazobactam; TM: tobramycin; 
ATM: aztreonam; FEP: cefepime; CS: colistin; PIP: piperacillin; TIC: ticarcillin; TCC: ticarcillin/clavulanic acid.  
 
3.3 Phage isolation and characterization 
 
The phage isolated from sewage water was referred as PA709. The stock of PA709 used 
in this study had a title of 1 x 108 PFU mL-1. The lysis plaques were round with a 1 mm 
diameter after 6h of incubation in TSA with 0.6% of agar at 37°C (Figure 3.2 a). The TEM 
results showed that the phage PA709 had an icosahedral head (60 nm) and a long 
contractile tail typical of the family Myoviridae (Figure 3.2 b). The analysis of the nucleic 
acid of phage was assessed using enzyme digestion (DNase I, RNase I). The nucleic acid was 
digested by DNase I but not by RNase I. This results indicate that the phage has DNA as 
nucleic acid (Figure 3.2 c).  
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Figure 3.2: Characterization of phage PA709. a) phage plaques; b) transmission electron micrograph image of phage 
particles. The bar represents a length of 50 nm; c) analysis of nucleic acid of phage; Lane M, molecular length marker; C+, 
control reaction with nucleic acid samples; SR, nucleic acid samples digested with Rnase I; CR, Control of Rnase I; SD, 
nucleic acid samples digested with Dnase I; CD, Control of Dnase I. 
 
The phage survival tests conducted in vitro show that phage PA709 is viable for more 
than 30 days, in the absence of the host. The concentration decreased 1 log in the first 24 
days and then reached a plateau (Figure 3.3 a). The ex vivo experiments of phage survival 
showed that phage PA709 remained viable in human skin during the study period of 7 days. 
The phage titer decreased 1 log in the absence of the host (Figure 3.3 b).  
 
Figure 3.3: Survival of phage PA 709. a) In vitro. Phage was added to PBS and incubated at 37 °C; b) Ex vivo. Phage 
was added to human skin and incubated at 37 °C; Error bars indicate the standard deviation. 
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3.4 Host range determination 
 
Phage PA709 exhibited a broad host spectrum. Thirty per cent of the 51 MDR P. 
aeruginosa clinical isolates were infected by the phage, 3 from HUC, 7 from ULSM, 4 from 
HIDP and 1 from Avelab Laboratory (Table 3.2). 
 
Table 3.2: Host range of the isolated bacteriophage against P. aeruginosa isolates 
Bacteria Assigned by Host range 
PA 17567 AVELAB + 
PA 709 HUC + 
PA 548 HUC + 
PA 519 HUC + 
PA 028 ULSM + 
PA 61 ULSM + 
PA 777 ULSM + 
PA 088 ULSM + 
PA 926 ULSM + 
PA 103 ULSM + 
PA 154 ULSM + 
PA 766 HIDP + 
PA 1 HIDP + 
PA 3 HIDP + 
PA 6 HIDP + 
 
Of the 15 isolates infected by phage, nine were chosen from different Portuguese 
hospitals (Aveiro, Coimbra and Matosinhos) for molecular typing. The genotyping box 
results showed that six of the nine isolates display different band patterns, which 
correspond to different genotypes (Figure 3.4). 
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Figure 3.4: BOX PCR for 9 isolates of P. aeruginosa. Lane M, molecular length marker. Lane C-, control reaction with 
no template DNA included during PCR. Lanes A to I, isolates PA 709 (HUC), PA 028 (ULSM), PA 17567 (AVELAB), PA 61 
(ULSM), PA 548 (HUC), PA 777 (ULSM), PA 088 (ULSM), PA 926 (ULSM) and PA 103 (ULSM), respectively. 
 
3.5 Identification of bacteria strains 
 
The six genetically different strains were sequenced. The results of the analysis of the 
gene sequences rRNA 16S are presented in Table 3.3. The results showed that, the 16s 
rDNA sequences of all strains show high homology with the Pseudomonas aeruginosa. 
 
Table 3.3: Results of the analysis of the gene sequences rRNA 16S 
Bacteria Assigned 
by 
Lane letter  
(Figure 3.4) 
Classificação RDP a 
Classe/Ordem/Family 
 
Identity 
BLAST-N 
% 
PA 709 HUC A 
Gammaproteobacteria 
 
Pseudomonadales 
 
Pseudomonadaceae 
Pseudomonas 
aeruginosa 
100% 
PA 028 ULSM B and F 100% 
PA 17567 AVELAB C 100% 
PA 61 ULSM D 99% 
PA 548 HUC E and G 100% 
PA 926 ULSM H and I 65% 
a  RDP classification - Ribossomal Database Project 
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3.6 Phage therapy in vitro 
 
In the control cultures (without phages), P. aeruginosa 709 reached densities of 107 CFU 
mL-1 after 6 hours of incubation (Figure 3.5 a). In presence of the phage, for higher MOI (10 
and 50), the number of viable bacteria decreased from 105 CFU mL-1 to 102 CFU mL-1, after 
4 hours of incubation (Figure 3.5 a). For these MOI the decrease of the target bacteria was 
more pronounced than for a MOI 0.5 (P < 0.05, ANOVA). With MOI 0.5, the number of 
viable bacteria decreased to 102 CFU mL-1 after 8 hours of incubation (Figure 3.5 a). The 
inoculation of a single dose of phage, for the three tested MOI, reduced the concentration 
of target bacteria by 5 logs, within the first 6 hours, but during the subsequent incubation 
the non infected bacteria grew and reached densities similar to the control.  
The number of inoculated phage remained constant after 2 hours of incubation 
increased with further incubation to 108 PFU ml-1 (Figure 3.5 b). 
 
 
Figure 3.5: Infection of P. aeruginosa at different MOI, in vitro. a) bacterial concentration; b) phage concentration. 
The results are the average of two independent experiments. Error bars indicate the standard deviation.  ●control 
PA709, ♦MOI 0.5, ▲MOI 10, ■ MOI 50 
 
The administration of a second dose of phage, tested only for the MOI of 10, of 
incubation did not increase the efficiency of phage therapy within 4 hours of incubation. 
The pattern of bacterial growth was similar to that observed when only one phage dose 
was applied (P>0.05, ANOVA) (Figure 3.6). 
a b 
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Figure 3.6: Control of P. aeruginosa by phage infection at a MOI of 10, in vitro. The results are the average of two 
independent experiments. Error bars indicate the standard deviation; ●control PA709, ▲ one dose of phage, ■ two 
doses of phage. At the time indicated by arrow, a second dose of PA709 phage was added to the culture.  
 
3.7 Phage therapy in ex vivo human skin 
 
At a MOI of 10, the number of viable bacteria decreased from 105 CFU cm-2 (0h) to 102 
CFU cm-2 after 4 hours of incubation, corresponding to a reduction of 4 logs. In the control 
samples (without phage), the P. aeruginosa 709 reached concentrations of 106 CFU cm-2 
after the same period of incubation (Figure 3.7). 
 
Figure 3.7: Control of P. aeruginosa by phage infection at a MOI of 10, in human skin (ex vivo).  The results are the 
average of two independent experiments. Error bars indicate the standard deviation; ● control PA709, ▲ MOI 10.  
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3.8 Detection of prophages in the host 
 
After the addition of mitomycin C to the P. aeruginosa 709 culture, no lysis plaques 
were observed before and after incubation with the phage suspension. As in the control, 
without mitomicin C, the spot test was negative, i.e, no lysis plaques were observed. 
 
3.9 Screening of host resistant strains 
 
The host bacteria did not develop resistance to phage infection after incubation in the 
presence of the phage suspension. All the isolated colonies collected after 8 and 10 hours 
of phage therapy in vitro at a MOI of 10, showed a clear zone in the TSA plates after 3-5 
successive bacterial replications in TSA. For the isolated colonies of the sample subjected to 
phage therapy after the first and second replications in TSA no lysis plaques were observed. 
After the first and second replications in TSA a clear zone was observed only in the control 
samples. 
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4 Discussion 
 
Pseudomonas aeruginosa is one of the most common opportunistic human pathogenic 
responsible for wound infections (Luzzaro et al., 2004). Systemic antibiotic therapy has 
little utility in patients with deep wounds, because of poor penetration of the antibiotic 
into the wound, being the infection difficult to eliminate (Gilakjan and Kropinski, 1999; 
Kutter et al., 2010). On the other hand, as seen in this study and in other works (Wang et 
al., 2006; Wright et al., 2009), the most commonly used topical antibiotics are not effective 
against P. aeruginosa, alternative topical antimicrobial treatments are needed. Phage 
therapy represents a potential approach to inactivate pathogenic microorganisms and has 
already show to be efficient against bacterial infections in humans and animals (Almeida et 
al., 2009; Housby and Mann, 2009; Wiggins and Alexander, 1985). 
The results of this study show that 1) the topical application of phage PA709 may 
effectively control human skin infections by P. aeruginosa 709 (bacteria reduction of 4 logs, 
after 2 hours of incubation); 2) the MOI of 10 and 50 are more effective than the MOI of 
0.5; 3) the application of a single phage dose may be sufficient; 4) the application of phage 
PA709 is safe (no lysogenic conversion was detected); 5) the phage PA709 is suitable for 
phage therapy, has a broad host range (infection of 30% of the tested P. aeruginosa 
isolates), infecting different genotypes of P. aeruginosa and a high survival (in vitro and in 
ex-vivo). 
The application of the bacteriophage PA709 on human skin artificially contaminated 
with P. aeruginosa 709 clearly reduces the number of viable bacteria by 4 logs after 2 hours 
of incubation. Although after 2 hours of incubation 2 logs of bacteria remain viable, the 
bacterial density may have decreased to a level low enough to be eliminated by the host 
immunitary system (Levin and Bull, 2004). As demonstrated by the mathematical model 
proposed by these authors the combination of phage and the host defenses are sufficient 
to keep the bacterial density below lethal threshold after phage therapy (Levin and Bull, 
2004).  
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According to the literature, the non-inactivation of the remaining bacteria can be due 
to the difficulty of viruses to find the host bacteria (Wiggins and Alexander, 1985), to non-
replicating conditition of the surviving bacteria that is physiologically refractory to phage 
infection (Bull et al., 2002; Levin and Bull, 2004) and to the development of resistance of 
the host to the phages (Levin and Bull, 2004). The results of this study show clearly that 
bacteria that re-grow after phage therapy were not resistant to PA709 phage. Similar 
results have been observed in other studies (Oliveira et al., 2009; Sillankorva et al., 2004). 
However, some authors attributed bacterial re-growth to the development of host 
resistance to the phages without actually testing the development of resistance (Andreatti 
Filho et al., 2007; Kutter et al., 2010). On the other hand, in this study, all the tested 
bacteria that re-grew after phage therapy regained sensitivity to the phages only after 3-5 
streak-plating steps on solid medium, which means that these bacteria are yet infected 
with viruses which prevent their infection by the newly added phages after their isolation. 
Thus, the hypothesis of re-growth due to the low probability of encounter between viruses 
and hosts bacteria is not likely. In fact, the increase of MOI of 10 to 50 did not increase the 
efficiency of phage therapy, which means that almost all bacteria are infected at the MOI 
of 10 that was the MOI used in vitro and in ex vivo phage therapy experiments. The 
occurrence of lysogeny which can also render the bacterium immune to not only the 
original phages but also to related phages (Skurnik and Strauch, 2006) could also explain 
the bacterial re-growth, but no evidence of lysogeny was observed during the phage 
therapy experiments. Induction by the addition of mitomycin C to isolated bacteria that 
remained viable after phage therapy was not observed. The hypothesis of non-replicating 
bacteria to be physiologically refractory to phage infection can possibly explain the 
bacterial re-grow after phage therapy treatment. 
The topical application of phage therapy by using gauze bandages soaked in phage 
suspension is suitable for topical use on wounds and was effective in the reduction of the 
concentration of infectious bacteria. Similar results were obtained when phage therapy 
was applied locally (Goode et al., 2003; Jikia et al., 2005). In addition, it was found that the 
normal skin microflora was not affected when this procedure was used (data not show) 
and the phage remain active for more than 7 days on the skin, which can help to avoid re-
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infection by the same bacteria. Up to our knowledge studies on phage survival in ex vivo 
experiments with human skin, are not available in current literature. However, a study of 
Kumari et al. (Kumari et al., 2010) using phage to treat burn wound infection caused by 
Pseudomonas aeruginosa PAO in BALB/c Mice showed that the titer of five different 
Pseudomonas phage injected in mice kept on decreasing in skin with increase in time and 
no phage could be isolated in skin samples after 36 h of phage treatment. 
Three MOI were tested in order to optimize the phage dose for the treatment of P. 
aeruginosa infections. High MOI are used when the experiments requires that most cells in 
the culture are infected, such as in the case of phage therapy. By contrast, low MOI are 
used when multiple cycles of infection are required. The MOI of 10 and 50 improved 
bacterial reduction relatively to the MOI of 0.5 such as observed in other studies (Goode et 
al., 2003; Huff et al., 2005). The reduction of Salmonella enteritidis and of Campylobacter 
jejuni by specific phages on excised chicken skin was investigated at different MOI (Goode 
et al., 2003). At a MOI of 1, phage reduced the two pathogens by < 1 log. At a MOI of 100-
1000, the number of bacteria was reduced by up 2 logs. Huff et al., also showed that 
application of phages in birds, to reduce Escherichia coli is only effective at a MOI of 10,000 
(Huff et al., 2005). When the culture was mixed with equal number of bacteriophage, 
mortality was reduced from 85 to 35%. However, in this study the difference of bacterial 
inactivation with MOI of 10 and of 50 was not significantly different. 
Several studies indicate that the application of a single dose of phage suspension is 
enough to inactive pathogenic bacteria (Biswas et al., 2002; Sulakvelidze et al., 2001). 
Contrarily to antibiotics, repeated administration is unnecessary because as long as the 
target bacterium is present, the phage will be able to replicate. The local proliferation of 
the phages at the site of infection may require less frequent phage administration in order 
to achieve the optimal therapeutic effect. The results obtained in the present experiments 
confirm this assumption, encouraging a single dose of phage administration. The 
application of a second dose of phages did not increase the effectiveness of P. aeruginosa 
inactivation.  
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The results indicate that phage PA709 has a broad host range (30% of the 51 MDR P. 
aeruginosa clinical isolates were infected by the phage), infecting different genotypes of P. 
aeruginosa collected in the three studied cities of Portugal (Aveiro, Coimbra and 
Matosinhos). The bacterial host molecular typing by BOX-PCR with the primer BOXA1R 
showed that the strains of P. aeruginosa isolated from the different cities, which were 
infected by the phage PA709, correspond to different genotypes and, consequently, this 
phage may be widely used to treat P. aeruginosa infections. 
The phage PA709 has an icosahedral head with a long contractile tail and a double 
stranded DNA molecule as nucleic acid, a morphology characteristic of members of the 
Myoviridae family. The morphology of the studied phage and the characteristics of the 
nucleic acid suggested that PA709 may be closely related to the P. aeruginosa phages KZ 
Lin68, Lin21, PTB80, NN, EL, and RU (Krylov et al., 2003) rather than with P. aeroginosa 
phages D3112 and B3 (Ceyssens et al., 2009; Gilakjan and Kropinski, 1999) and KMV, LKD16 
and LKA1 (Lavigne et al., 2003; Lavigne et al., 2008) which were classified as Siphoviridae 
and Podoviridae family, respectively. 
Phage PA709 presents some interesting features, namely high efficiency in the 
inactivation of MDR P. aeruginosa, a broad host range and high stability in stock 
suspensions and in ex vivo human skin. All these attributes make this phage very promising 
for the treatment of P. aeruginosa skin wound infections. However, more phages should be 
isolated in the future, for the formulation of cocktails which might improve the inactivation 
efficiency against P. aeruginosa human skin infections. 
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Abstract 
 
The rising prevalence of antibiotic resistant bacterial strains represents a serious 
therapeutic challenge for clinicians. Phage therapy has been regarded as a viable 
alternative to inactivate multidrug-resistant (MDR) strains. Pseudomonas 
aeruginosa is one of the most common MDR Gram-negative bacterium causing 
wound infections. The main goal of this study was to evaluate the efficiency of 
phage therapy against MDR P. aeruginosa in vitro and in ex vivo (human skin) 
experiments. A phage suspension (108 PFU mL-1) was obtained using the clinical 
strain P. aeruginosa 709 as host. The ability of the phage to cause inactivation of 
different P. aeruginosa isolates was evaluated in vitro and in ex vivo, using a 
multiplicity of infection of 0.5 to 50. The number of MDR P. aeruginosa 709 in 
the human skin in the presence of the phage decreased 4 logs after 2 hours of 
incubation. The application of a second dose of phage did not increase the 
efficiency of the therapy. The results of this study indicate that the topical 
application of phage PA709 efficiently inactivates MDR P. aeruginosa 709 
clinical strain, being a good candidate as therapeutic agent for the treatment of 
human wound infections caused by MDR P. aeruginosa 709. The broad host 
range of the phage, including different genotypes of P. aeruginosa, suggests that 
this phage can be widely used to treat P. aeruginosa infections. 
 
Introduction 
 
Chemotherapy has shown to be a rapid and effective 
method to treat microbial infections but the regular use of 
antimicrobials has lead to the development of drug 
resistance in common pathogenic strains (Pai et al., 2001; 
Wróblewska, 2006). Although novel classes of antibiotics 
may be developed, the perspective that bacteria will 
eventually develop resistance to the new drugs (Walsh, 
2003) emphasizes the risk that effective antibiotics may 
not be available to treat seriously ill patients in the near 
future. Because of the increasing costs of the research on 
new antimicrobials, the pharmaceutical industry has 
diminished its investment in this field, despite the 
increasing frequency and severity of antimicrobial 
resistance cases. This has dramatically weakened the so-
called pipeline for new antibiotic compounds, particularly 
against Gram-negative bacteria. 
As a result, the development of a novel, convenient and 
inexpensive methods, such as phage therapy, for fighting 
microbial diseases is required. Phage therapy research is 
as alive and full of promises nowadays as it was during its 
apogee of the 1960s and early 1970s (Comeau et al., 
2008). Coincidentally, there was a parallel reawakening of 
interest in exploiting the enormous diversity of viruses that 
infect bacterial pathogens for phage therapy approaches to 
the control or prevention diseases of bacterial origin 
(Housby and Mann, 2009; Sulakvelidze et al., 2001). 
The use of bacteriophage therapy requires, however, a 
detailed understanding of the phage-bacteria interaction 
and awareness of various novel kinetics phenomena not 
known in conventional drug treatments. 
The understanding of phage-bacteria interaction helps to 
know how the phage can control bacterial growth. This 
control can be achived by maintaining the density of 
phage convenient values, so that the phages can 
effectively reduce the rate of replication of the host (Levin 
and Bull, 2004), avoiding their re-growth. However, 
studies in vitro have shown that bacteria can re-grow after 
some hours of phage therapy (Andreatti Filho et al., 2007; 
Heo et al., 2009; Kumari et al., 2010; Loc Carrillo et al., 
2005). Some authors interpreted that this gradual increase 
of bacterial density is due to the emergence of strains 
resistant to the phages. Nevertheless, some of these studies 
did not actually experimentally test the development of 
bacterial resistance, only consider that the bacterial re-
growth can be due to the development of resistance to 
phage infection (Andreatti Filho et al., 2007; Kumari et 
al., 2010). Other authors interpreted the re-growth as an 
indication that bacteriophages do not infect the host 
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bacteria when viral density is below the host cell threshold 
(Wiggins and Alexander, 1985). After several hours of 
incubation, the host may become a non-replicating 
bacterial population (slow bacterial growth or bacterial 
populations structured as biofilms) preventing the phage 
induced cell lysis (Bull et al., 2002; Levin and Bull, 2004). 
It is important to note that this increase is not observed in 
vivo since the combination of phage and the host defenses 
are sufficient to keep the bacterial density below lethal 
threshold after phage therapy (Levin and Bull, 2004). 
Phage therapy only needs to decrease the numbers of 
infecting bacteria to a level from which the host defenses 
can take care of the remaining bacteria (Levin and Bull, 
2004). 
Kinetics theory of phage therapy predicts that the average 
number of phage per bacterium, that is, the multiplicity of 
infection (MOI), the number of phage doses applied and 
the route how the phages are applied, could be critical to 
the efficiency of bacterial inactivation.  
It has been shown in vitro conditions that the reduction of 
pathogenic bacteria increased with the increase of the MOI 
(Goode et al., 2003). The same was observed in vivo 
experiments with mice infected with a lethal imipenem-
resistant P. aeruginosa bacteremia (Huff et al., 2005).  
Contrarily to antibiotics, the application of a single dose 
appears to be sufficient to control bacterial growth. In vivo 
studies demonstrated that, through different routes of 
phage application, a single dose rescued 100% of the 
bacteremic tested animals (Smith and Huggins, 1982). 
Several studies have shown that for the same type of 
infection, the phage can be applied through different 
routes, some more suitable than others (McVay et al., 
2007; Watanabe et al., 2007). McVay et al. (McVay et al., 
2007) showed that the location where the phages were 
injected change the survival rate of mice. The application 
of phage locally to eliminate wound infections in human 
skin (Jikia et al., 2005) and in chicken skin (Goode et al., 
2003) instead of injecting, has shown good results.  
To understand the phage-bacteria interaction, in vitro tests 
are not sufficient. In vivo tests are as necessary as 
cumbersome and expensive. Tests ex vivo do not fully 
mimic the in vivo growth conditions, but allow 
experimentation under conditions identical to in vivo but 
under more controlled conditions. This methodology 
combines the advantages of in vivo with the flexibility of 
the in vitro. Ex vivo conditions allow experimentation 
under more controlled conditions than possible in in vivo 
experiments, at the expense of altering the natural 
environment.  
Pseudomonas aeruginosa is the main pathogen that 
colonize the skin injury, cause wound infections (Church 
et al., 2006; McVay et al., 2007) and other diseases such 
as pneumonia, bacteremia, meningitis, urinary tract 
infection in immunocompromised individuals and 
hospitalized patients  (Rossolini et al., 2007; Wróblewska, 
2006). Currently, this is one of the most common 
multidrug-resistant (MDR) strains in hospitalized patients 
(Bergogne-Berezin and Towner, 1996; Rossolini et al., 
2007). Although there are several reports available in 
literature where phages have been used to treat variety of 
bacterial infections in animal model systems (Huff et al., 
2005; Kumari et al., 2010; McVay et al., 2007; Wang et 
al., 2006), the information on the treatment of skin wound 
infection is scanty. Phages therapy was successfully tested  
 
Fig. 1. Relative frequency (%) of susceptibility, intermediate 
susceptibility and resistance to a range of common antibiotics 
among the 51 isolates. R: resistant; S: sensitive and I: 
intermediate; NA: amikacin; CAZ: ceftazidime; CIP: 
ciprofloxacin; GM: gentamicin; IPM: imipenem; MEM: 
meropenem; TZP: piperacillin/tazobactam; TM: tobramycin; 
ATM: aztreonam; FEP: cefepime; CS: colistin; PIP: piperacillin; 
TIC: ticarcillin; TCC: ticarcillin/clavulanic acid. 
 
 
in the prevention of the  rejection of skin implants in pigs 
(Soothill, 1992) and were also used in the treatment of 
skin wound infections by P. aeruginosa (Kumari et al., 
2010; McVay et al., 2007). Recently, a cocktail of three 
different P. aeruginosa specific phages induced protection 
against fetal infection with P. aeruginosa in mice (McVay 
et al., 2007). From these, a clinical trial in which a cocktail 
of phages targeted against P. aeruginosa and 
Staphylococcus aureus was initiated in Belgium 
(Merabishvili et al., 2009). 
The main objective of this study was to evaluate the 
efficiency of phage therapy to control MDR P. aeruginosa 
infections in human skin wounds. The kinetics of phage-
bacteria interactions were examined in vitro and in ex vivo 
in order to determine the course of the infection and 
provide basis to select the most suitable protocol for 
subsequent in vivo experiments. 
 
Experimental 
 
Bacterial strains, growth conditions and identification 
 
MDR Pseudomonas aeruginosa strains were isolated at 
the microbiology laboratory of the University Hospital of 
Coimbra (Hospital Universitário de Coimbra - HUC) (4 
isolates), Local Health Unit of Matosinhos (Unidade Local 
de Saúde de Matosinhos - Pedro Hispano - ULSM) (27 
isolates), Infante D. Pedro Hospital (Hospital Infante D. 
Pedro – Aveiro -HIDP) (17 isolates) and Avelab 
Laboratory (3 isolates). The MDR Pseudomonas 
aeruginosa 709 isolated by HUC was used as host to 
produce the phage stock suspension. The system 
BioMerieux Vitek 2® (BioMerieux) was employed to 
identify and characterize the profile of antibiotic 
susceptibility of the bacteria isolates. 
The 51 MDR isolates used in this study were cultivated in 
Tryptic Soy Broth (TSB; Merck) with agitation of 160 
rpm at 37ºC for 4 hours. For each assay, an aliquot of this 
culture (240 µL) was subcultured in 30 mL of TSB 
medium and grew overnight at 37 °C under stirring (120 
rpm) to reach an optical density (OD620) of ≈1.0, 
corresponding to ≈108 cells mL-1.  
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Fig. 2 Macroscopic and microscopic characterization of phage 
PA709. a phage plaques; b transmission electron micrograph 
image of phage particles. The bar represents a length of 50 nm; c 
survival of phage PA 709 in vitro. Phage was added to PBS and 
incubated at 37 °C; d survival of phage PA 709 ex vivo. Phage 
was added to human skin and incubated at 37 °C; Error bars 
indicate the standard deviation. 
 
 
Phage isolation  
 
Sewage water samples collected from HUC wastewater 
treatment plant were filtered by 0.45 µm-pore-size 
polycarbonate membranes (Millipore). The filtrate was 
added to a fresh bacterial culture in TSB. The mixture was 
incubated at 37ºC for 5 hours at 100 rpm and then 
centrifuged (10,000 x g, 10 minutes) (Thermo Haraeus 
Pico). The phage titer was determined by the double-layer 
method (Adams, 1959) using the centrifugated supernatant 
as phage suspension and Tryptic Soy Agar (TSA; Difco) 
as culture medium. The plates were incubated at 37ºC and 
examined for lysis plaques after 12 hours. Two more 
successive single-plaque isolations were performed to 
obtain pure phage stocks. The diameter of the lysis 
plaques was determined after incubation of the double-
layer cultures. Phage stocks were stored at 4°C with 1% 
chloroform. 
 
Phage nucleic acid extraction 
 
Before nucleic acid extraction, phage particles were 
precipitated with polyethylene glycol (PEG) and separated 
by centrifugation (10,000 x g, 10 minutes). The pellets 
was resuspended in TE buffer [10 mM Tris HCl, 1mM 
ethylenediamine tetraacetic acid (EDTA), pH 8.0] 
(Sambrook and Russell, 2001). Extractions of nucleic acid 
from phage particles was performed using the protocol of 
Griffiths et al. (Griffiths et al., 2000). In order to amplify 
the phage nucleic acid kit was used the TempliPhi DNA 
Sequencing Template Amplification kit (Amersham 
Biosciences) was used as described by the manufacturer, 
with some adaptations. The template (2 µL) was added to 
2 µL of distilled water and to 6 µL of sample buffer. A 
reaction premix was prepared (12 µL reaction buffer, 0.8 
µL BSA (0.25 µg/µL) and 0.5 µL enzyme mix) and after 
denaturation, 7 µL of this premix was added to each  
 
Fig. 3 Infection of P. aeruginosa at different MOI, in vitro. a 
bacterial concentration; b phage concentration. The results are the 
average of two independent experiments. Error bars indicate the 
standard deviation; ● control P. aeruginosa 709, ♦ MOI 0.5, 
▲MOI 10, ■ MOI 50. 
 
 
sample and incubated at 30°C for 4.5 h. The reaction was 
terminated by heating at 65°C for 10 min.  
 
Phage nucleic acid characterization 
 
The nucleic acid extracts were subjected to digestion with 
DNase I (Ambion) and RNase I (Sigma Aldrich) as 
described by manufacturer. The reactions were terminated 
by heating at 80ºC for 5 min. Nucleic acid yield was 
observed through agarose gel electrophoresis (1% agarose 
gel electrophoresis at 80 V). 
 
Preparation of phages for transmission electron 
microscopy (TEM) 
 
The phage suspension was centrifuged directly onto 
formvar-coated carbon-stabilized 400 mesh copper 
electron microscopy grids (Labometer) as described by 
Almeida et al. (Almeida et al., 2001). The viruses were 
ultracentrifuged at 100,000 x g for 1.30 h at 25ºC in a 
Beckman L8-80K ultracentrifuge equipped with a swing-
out rotor (SW28). After centrifugation, the grids were 
negatively stained with 1.5% (w/v) uranyl acetate for 60 
seconds (Bratbak and Heldal, 1993), air-dried and 
examined with a Hitachi H9000 transmission electron 
microscope at a magnification of 100,000× and an 
accelerating voltage of 200 kV. 
 
Phage host range analysis 
 
The 51 isolates of MDR P. aeruginosa were used for the 
determination of phage host range. Fresh bacterial cultures 
were separately added to molten soft TSA, overlaid on 
solid TSA and spotted with 10 μL of the phage 
suspension. Cultures were incubated at 37ºC for 6 hours. 
Positive infection detected by the occurrence of lysis 
plaques. Each strain was tested in two independent assays. 
 
Phage therapy in vitro 
 
In order to obtain 0.5, 10 and 50 MOI, 105 CFU mL-1 of P. 
aeruginosa 709 and a set of serial dilutions of phage 
suspension (104 to 106 PFU mL-1 ) were inoculated in TSB 
and incubated at 37ºC without agitation. For the MOI 10 
assay, a second phage dose application (106 PFU mL-1) 
was also tested. The second dose was applied 4 hours after 
the first one. In the controls, the phage was not added to 
the bacterial cultures. Aliquots were collected at time 0 
and 2, 4, 6, 8, 12 and 18 h of incubation for host and phage  
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Fig. 4 Control of P. aeruginosa by phage infection at a MOI of 
10, in vitro. The results are the average of two independent 
experiments. Error bars indicate the standard deviation; ● control 
P. aeruginosa 709, ▲ one dose of phage, ■ two doses of phage. 
At the time indicated by arrow, a second dose of PA709 phage 
was added to the culture. 
 
 
quantification. For quantification of the host, aliquots were 
serially diluted, and pour-plated in duplicate, and 
incubated at 37ºC for 24 h. The phage title was determined 
in duplicate, by double- layered method, followed by 
incubation 37ºC for 18 h. Two independent experiments 
were conducted and the results were averaged. 
 
Phage therapy in ex-vivo human skin 
 
Samples of human skin, obtained from surgical 
procedures, were cut into sections of 10 cm2, disinfected 
with povidone-iodine (PVPI) 10% and washed with saline 
solution. The skin sections were individually transferred to 
sterile petri dishes. An aliquot of 200 µL of an overnight 
culture of strain P. aeruginosa 709 was inoculated on the 
skin samples and the inoculum was evenly spread over the 
surface using a glass spreader. Gauze bandages soaked 
with phage solution (pH=7.3) were placed directly on the 
inoculated skin which was then incubated at 37°C in a 
humid atmosphere. Surface samples from the skin were 
collected from a defined area with cotton swabs at time 0 
and 2, 4, 6, 8, 12 and 18 h of incubation and washed in 
PBS. The sample suspension was pour-plated, in duplicate 
on MacConkey agar (Merck) for quantification of the host 
bacteria and the results were expressed as CFU cm-2. For 
the quantification of the phage, the PBS suspension was 
serially diluted, plated by the double- layer method, 
incubated at 37°C during 18 h and the results expressed as 
PFU cm-2. The phage suspension was not added to the 
controls that were otherwise treated as the tests. 
Experiments were conducted in duplicate and the results 
were averaged. 
 
Phage survival in vitro 
 
An aliquot of 1 mL of phage suspension (107 PFU mL-1) 
was inoculated in PBS and incubated at 37ºC without 
agitation. Sub-samples were collected at time 0 and 9, 15, 
21, 24, 27, 30 and 36 days incubations for phage 
quantification. The phage was quantified, in duplicate, by 
the double- layer method. Two independent assays were 
conducted and the the results were averaged. 
 
Phage survival in ex-vivo human skin 
 
Gauze bandages soaked in the phage solution (107 PFU 
mL-1) were place over samples of human skin and kept at 
37°C in a humid atmosphere. Skin samples were collected 
at time 0 and 4, 5, 6 and 7 days of incubation for phage 
quantification. The phage was quantified, in duplicate, 
using the double- layer method. Two independent assays 
were conducted and the results were averaged. 
 
Detection of prophages in the host 
 
Mitomycin C (Sigma Chemical) was added to a P. 
aeruginosa 709 culture (1 μg mL-1) before and after 10 
hours of incubation at 37°C with the phage PA709. The 
culture was incubated overnight at 37ºC and centrifugated 
(10,000 x g, 10 minutes) (Thermo Haraeus Pico). The spot 
test was performed using the supernatant as phage 
suspension. In the control, mitomycin C was not added. 
Two independent assays were conducted and the results 
were averaged. 
 
Screening of host resistant strains 
 
After 8 and 10 hours of incubation at 37°C with the phage 
PA709, for MOI 10, an aliquot was plated in TSA in order 
to isolate bacteria colonies. Cultures were incubated at 
37ºC overnight. Five isolated colonies were purified by the 
streak-plating technique (3-5 steps) and the purified 
isolates were cultured in TSA, in order to remove phage 
particles from the bacteria. To check if the strain remained 
sensitive to the phage, the isolated colonies were 
inoculated separately in TSB and tested by the spot 
procedure. Two independent assays were conducted for 
each isolate. 
 
Statistical analyses 
 
Statistical analysis was performed by using SPSS (SPSS 
15.0 for Windows, SPSS Inc., USA). Normal distributions 
were assessed by the Kolmogorov-Smirnov test and 
homogeneity of variances was assessed by the Levene test. 
The significance of the difference in phage inactivation 
with different MOI and with different doses was evaluated 
by one-way ANOVA with the Bonferroni post hoc test. A 
value of P < 0.05 was considered as significant. 
 
 
Results 
 
Resistance profiling of the bacterial strains 
 
Among the 51 bacteria studied, 70% of isolates showed 
resistance to ciprofloxacin, piperacillin/tazobactam, 
piperacillin and ticarcillin/clavulanic acid, 50% to 70% 
were resistant to ceftazidime, imipenem, meropenem and 
ticarcillin. The most effective antibiotics against these 
strains are amikacin, tobramycin and colistin with a of 
80%, 80% and 100% respectively (Fig. 1). 
 
Phage characterization 
 
The phage isolated from sewage water was referred as 
PA709. The stock of PA709 used in this study had a title 
of 1 x 108 PFU mL-1. The lysis plaques were round with a 
1 mm diameter after 6h of incubation in TSA with 0.6% of 
agar at 37°C (Fig. 2a). The analysis of the nucleic acid of 
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phage was assessed using enzyme digestion (DNase I, 
RNase I). The nucleic acid was digested by DNase I but 
not by RNase I. This results indicate that the phage has 
DNA as nucleic acid. The TEM results showed that the 
phage PA709 had an icosahedral head (60 nm) and a long 
contractile tail typical of the family Myoviridae (Fig. 2b).  
The phage survival tests conducted in vitro show that 
phage PA709 is viable for more than 30 days, in the 
absence of the host. The concentration decreased 1 log in 
the first 24 days and then reached a plateau (Fig. 2c). The 
ex vivo experiments of phage survival showed that phage 
PA709 remained viable in human skin during the study 
period of 7 days. The phage titer decreased 1 log in the 
absence of the host (Fig.2d). 
 
 
 
Host range determination 
 
Phage PA709 exhibited a broad host spectrum. Thirty per 
cent of the 51 MDR P. aeruginosa clinical isolates were 
infected by the phage, 3 from HUC, 7 from ULSM, 4 from 
HIDP and 1 from Avelab Laboratory. 
 
Phage therapy in vitro 
 
In the control cultures (without phages), P. aeruginosa 
709 reached densities of 107 CFU mL-1 after 6 hours of 
incubation (Fig. 3a). In presence of the phage, for higher 
MOI (10 and 50), the number of viable bacteria decreased 
from 105 CFU mL-1 to 102 CFU mL-1,after 4 hours of 
incubation (Fig. 3a). For these MOI the decrease of the 
target bacteria was more pronounced than for a MOI 0.5 
(P < 0.05, ANOVA). With MOI 0.5, the number of viable 
bacteria decreased to 102 CFU mL-1 after 8 hours of 
incubation (Fig. 3a). 
The inoculation of a single dose of phage, for the three 
tested MOI, reduced the concentration of target bacteria 
by 5 logs, within the first 6 hours, but during the 
subsequent incubation the non infected bacteria grew and 
reached densities similar to the control. The number of 
inoculated phage remained constant after 2 hours of 
incubation increased with further incubation to 108 PFU 
ml-1 (Fig. 3b). 
 
 
The administration of a second dose of phage, tested only 
for the MOI of 10, of incubation did not increase the 
efficiency of phage therapy within 4 hours of incubation. 
The pattern of bacterial growth was similar to that 
observed when only one phage dose was applied (P>0.05, 
ANOVA) (Fig. 4).  
 
Phage therapy in ex vivo human skin 
 
At a MOI of 10, the number of viable bacteria decreased 
from 105 CFU cm-2 (0h) to 102 CFU cm-2 after 4 hours of 
incubation, corresponding to a reduction of 4 logs. In the 
control samples (without phage), the P. aeruginosa 709 
reached concentrations of 106 CFU cm-2 after the same 
period of incubation (Fig. 5). 
 
Detection of prophages in the host 
 
 
Fig. 5 Control of P. aeruginosa by phage infection at a MOI of 
10, in human skin (ex vivo).  The results are the average of two 
independent experiments. Error bars indicate the standard 
deviation; ● control P. aeruginosa 709, ▲ MOI 10. 
 
 
After the addition of mitomycin C to the P. aeruginosa 
709 culture, no lysis plaques were observed before and 
after incubation with the phage suspension. As in the 
control, without mitomicin C, the spot test was negative, 
i.e, no lysis plaques were observed. 
 
Screening for resistance to phage infection 
 
The host bacteria did not develop resistance to phage 
infection after incubation in the presence of the phage 
suspension. All the isolated colonies collected after 8 and 
10 hours of phage therapy in vitro at a MOI of 10, showed 
a clear zone in the TSA plates after 3-5 successive 
bacterial replications in TSA. For the isolated colonies of 
the sample subjected to phage therapy after the first and 
second replications in TSA no lysis plaques were 
observed. After the first and second replications in TSA a 
clear zone was observed only in the control samples.  
 
Discussion 
 
Because of the poor penetration of antibiotics in skin 
wounds, systemic antibiotherapy has often a limited 
success in the treatment of this type of infections (Jikia et 
al., 2005; Kutter et al., 2010). The results of this study 
show that 1) the topical application of phage PA709 may 
effectively control human skin infections by P. aeruginosa 
709 (bacteria reduction of 4 logs, after 2 hours of 
incubation); 2) the MOI of 10 and 50 are more effective 
than the MOI of 0.5; 3) the application of a single phage 
dose may be sufficient; 4) the application of phage PA709 
is safe (no lysogenic conversion was detected); 5) the 
phage PA709 is suitable for phage therapy, has a broad 
host range (infection of 30% of the tested P. aeruginosa 
isolates), infecting different genotypes of P. aeruginosa 
and a high survival (in vitro and in ex-vivo). 
The application of the bacteriophage PA709 on human 
skin artificially contaminated with P. aeruginosa 709 
clearly reduces the number of viable bacteria by 4 logs 
after 2 hours of incubation. Although after 2 hours of 
incubation 2 logs of bacteria remain viable, the bacterial 
density may have decreased to a level low enough to be 
eliminated by the host immunitary system (Levin and 
Bull, 2004). As demonstrated by the mathematical model 
proposed by these authors the combination of phage and 
the host defenses are sufficient to keep the bacterial 
-61- 
 
density below lethal threshold after phage therapy (Levin 
and Bull, 2004).  
According to the literature, the non-inactivation of the 
remaining bacteria can be due to the difficulty of viruses 
to find the host bacteria (Wiggins and Alexander, 1985), 
to non-replicating conditition of the surviving bacteria that 
is physiologically refractory to phage infection (Bull et al., 
2002; Levin and Bull, 2004) and to the development of 
resistance of the host to the phages (Levin and Bull, 2004). 
The results of this study show clearly that bacteria that re-
grow after phage therapy were not resistant to PA709 
phage. Similar results have been observed in other studies 
(Oliveira et al., 2009; Sillankorva et al., 2004). However, 
some authors attributed bacterial re-growth to the 
development of host resistance to the phages without 
actually testing the development of resistance (Andreatti 
Filho et al., 2007; Kutter et al., 2010). On the other hand, 
in this study, all the tested bacteria that re-grew after 
phage therapy regained sensitivity to the phages only after 
3-5 streak-plating steps on solid medium, which means 
that these bacteria are yet infected with viruses which 
prevent their infection by the newly added phages after 
their isolation. Thus, the hypothesis of re-growth due to 
the low probability of encounter between viruses and hosts 
bacteria is not likely. In fact, the increase of MOI of 10 to 
50 did not increase the efficiency of phage therapy, which 
means that almost all bacteria are infected at the MOI of 
10 that was the MOI used in vitro and in ex vivo phage 
therapy experiments. The occurrence of lysogeny which 
can also render the bacterium immune to not only the 
original phages but also to related phages (Skurnik and 
Strauch, 2006) could also explain the bacterial re-growth, 
but no evidence of lysogeny was observed during the 
phage therapy experiments. Induction by the addition of 
mitomycin C to isolated bacteria that remained viable after 
phage therapy was not observed. The hypothesis of non-
replicating bacteria to be physiologically refractory to 
phage infection can possibly explain the bacterial re-grow 
after phage therapy treatment. 
The topical application of phage therapy by using gauze 
bandages soaked in phage suspension is suitable for 
topical use on wounds and was effective in the reduction 
of the concentration of infectious bacteria. Similar results 
were obtained when phage therapy was applied locally 
(Goode et al., 2003; Jikia et al., 2005). In addition, it was 
found that the normal skin microflora was not affected 
when this procedure was used (data not show) and the 
phage remain active for more than 7 days on the skin, 
which can help to avoid re-infection by the same bacteria. 
Up to our knowledge studies on phage survival in ex vivo 
experiments with human skin, are not available in current 
literature. However, but a study of Kumari et al. (Kumari 
et al., 2010) using phage to treat burn wound infection 
caused by Pseudomonas aeruginosa PAO in BALB/c 
Mice showed that the titer of five different Pseudomonas 
phage injected in mice kept on decreasing in skin with 
increase in time and no phage could be isolated in skin 
samples after 36 h of phage treatment. 
Three MOI were tested in order to optimize the phage 
dose for the treatment of P. aeruginosa infections. High 
MOI are used when the experiments requires that most 
cells in the culture are infected, such as in the case of 
phage therapy. By contrast, low MOI are used when 
multiple cycles of infection are required. The MOI of 10 
and 50 improved bacterial reduction relatively to the MOI 
of 0.5 such as observed in other studies (Goode et al., 
2003; Huff et al., 2005). At a MOI of 1, specific phages 
reduced the concentration of Salmonella enteritidis and 
Campylobacter jejuni on excised chicken skin by < 1 log 
but with MOI of 100-1000, the concentration of bacteria 
was reduced by as much as 2 logs (Goode et al., 2003). 
The application of phages in birds, to reduce Escherichia 
coli was only effective at a MOI of 10,000 and when the 
culture was mixed with equal number of bacteriophage, 
mortality was reduced from 85 to 35% (Huff et al., 2005). 
However, in this study the difference of bacterial 
inactivation with MOI of 10 and of 50 was not 
significantly different (Huff et al., 2005).  
The observation that that the application of a single dose 
of phage suspension may be sufficient to inactivate 
pathogenic bacteria is not new (Biswas et al., 2002; 
Sulakvelidze et al., 2001). Contrarily to antibiotics, 
repeated administration is unnecessary because as long as 
the target bacterium is present, the phage will be able to 
replicate. The local proliferation of the phages at the site 
of infection may require less frequent phage 
administration in order to achieve the optimal therapeutic 
effect. The results obtained in the present experiments 
confirm this assumption, encouraging a single dose of 
phage administration. The application of a second dose of 
phages did not increase the effectiveness of P. aeruginosa 
inactivation.  
The results indicate that phage PA709 has a broad host 
range (30% of the 51 MDR P. aeruginosa clinical isolates 
were infected by the phage), infecting different genotypes 
of P. aeruginosa collected in the three studied cities of 
Portugal (Aveiro, Coimbra and Matosinhos). The bacterial 
host molecular typing by BOX-PCR with the primer 
BOXA1R (data not show) showed that the strains of P. 
aeruginosa isolated from the different cities (North and 
Center of Portugal), which were infected by the phage 
PA709, correspond to different genotypes and, 
consequently, this phage may be widely used to treat P. 
aeruginosa infections. 
The phage PA709 has an icosahedral head with a long 
contractile tail and a double stranded DNA molecule as 
nucleic acid, a morphology characteristic of members of 
the Myoviridae family. The morphology of the studied 
phage and the characteristics of the nucleic acid suggested 
that PA709 may be closely related to the P. aeruginosa 
phages KZ Lin68, Lin21, PTB80, NN, EL, and RU 
(Krylov et al., 2003) rather than with P. aeroginosa 
phages D3112 and B3 (Ceyssens et al., 2009; Gilakjan and 
Kropinski, 1999) and KMV, LKD16 and LKA1 (Lavigne 
et al., 2003; Lavigne et al., 2008) which were classified as 
Siphoviridae and Podoviridae family, respectively. 
Phage PA709 presents some interesting features, namely 
high efficiency in the inactivation of MDR P. aeruginosa, 
a broad host range and high stability in stock suspensions 
and in ex vivo human skin. All these attributes make this 
phage very promising for the treatment of P. aeruginosa 
skin wound infections. However, more phages should be 
isolated in the future, for the formulation of cocktails 
which might improve the inactivation efficiency against P. 
aeruginosa human skin infections. 
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